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Abstract 
 
In healthy higher organisms the immune system is in a tight balance between 
sensitivity to pathogens and tolerance of self-structures. In autoimmune diseases like 
rheumatoid arthritis this steady state is imbalanced. Immune cells and antibodies, 
which are meant for pathogen clearence are suddenly prone to attack self-structures 
and promote inflammation of healthy tissue. A standard model to study 
immunological mechanisms of rheumatoid arthritis is the chicken collagen-induced 
arthritis (CIA) mouse model, where the immune response is characterized by high 
titers of IgG antibodies reactive against self-collagen type II (CII), a protein 
component of the synovial fluid in joints. Autoreactive IgG!s are potent mediators of 
inflammatory responses in self-tissues, but their effector function depends on the 
structure of one N-linked oligosaccharide in the effector region of IgG antibodies (Fc 
region). Recent findings have suggested that terminal sialic acid on this Fc-glycan 
provides antiinflammatory effector properties to IgG!s. Desialylation leads to a shift 
and gives the same IgG antibodies pathogenic effector functions.  
The goal of this diploma thesis was to investigate the therapeutic potential of antigen-
specific sialylated IgG antibodies in CIA. We established a CIA mouse model, where 
we were the first to show an antigen-specific prevention from the development of 
arthritis with sialylated anti-CII IgG1 antibodies that were cloned from freely 
accessible sequences described in the literature. We could show that enzymatic 
glycosylation of antibodies switched the effector function from pro- to 
antiinflammatory. These findings strongly support the theory of antiinflammatory 
activities of sialylated recombinant IgG!s, which could provide a potent future tool for 
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preventing the development of or even treat autoimmune diseases antigen-
specifically. 
 Zusammenfassung 
Im gesunden Organismus höher entwickelter Lebewesen bewegt sich das 
Immunsystem zwischen Sensibilität gegenüber Krankheitserregern und Toleranz 
gegenüber körpereigenen Strukturen. Bei Autoimmunerkrankungen wie 
Rheumatoider Arthritis gerät diese Balance aus dem Gleichgewicht. Immunzellen und 
Antikörper, die eigentlich für die Bekämpfung von Pathogenen zuständig sind, 
beginnen dabei körpereigenes Gewebe zu attackieren, wobei 
Entzündungsreaktionen hervorgerufen werden. Ein Standardmodell zur 
Untersuchung immunologischer Mechanismen bei Rheumatoider Arthritis ist das 
Hühnerkollagen-induzierte Arthritis (CIA) Mausmodell, dessen Krankheitsbild von 
hohen IgG-Antikörpertitern gekennzeichnet ist. Autoreaktive Antikörper richten sich 
dabei gegen körpereigenes Kollagen Typ II (CII) in der Gelenksflüssigkeit und rufen 
dort Gelenksentzündungen hervor. Dieser pathogene Mechanismus ist vor allem von 
der Glykosylierungsstruktur im Effektorteil (Fc) der IgG-Antikörper abhängig. Aktuelle 
Studien zeigen, dass terminale Sialinsäure an dieser Zuckerkette den Antikörpern 
entzündungshemmende Eigenschaften verleiht. De-sialylierte IgG Antikörper werden 
stattdessen mit inflammatorischen Effektorwirkungen in Verbindung gebracht.  
Die Untersuchung des therapeutischen Potentials dieser sialylierten Antiköper bei 
CIA war Ziel meiner Diplomarbeit. Dazu etablierten wir ein CIA Mausmodell, an 
welchem wir erstmalig zeigen konnten, dass sialylierte Anti-CII-Antikörper die 
Ausdehnung von Arthritis verhindern konnten. Wir konnten zeigen, dass 
rekombinante Antiköper, deren Sequenzen in der Literatur frei zugänglich waren, 
durch enzymatische Glykosylierung ihre Effektorwirkung von entzündungsfördernd 
auf –hemmend wechselten. Diese Erkenntnisse untermauern die These, dass 
12 Zusammenfassung 
 
sialylierte IgG-Antikörper entzündungshemmende Aktivitäten besitzen und somit 
zukünftig eine potente Waffe zur Prävention oder gar Behandlung von 
Autoimmunerkrankungen darstellen können.  
 
 
  
1. Introduction 
1.1. The Immune System 
1.1.1. A Defense Machinery  
The immune system of mammals provides a defence machinery against many kind of 
malignant influences that may harm the integrity of the organism. Besides toxins, 
foreign pathogens like viruses, bacteria and microbes are main targets of defence as 
well as abnormal self-structures like tumor cells of the host itself. The specificity of 
the immune system can potentially be directed against any molecular structure. But 
to avoid the problem that the immune system reacts against host self-structures, 
autoreactive components are deleted during developmental checkpoints. In healthy 
human individuals or animal models like mice the immune system is in a tight 
balance between sensitivity against pathogens and tolerance of self-structures, food 
and harmless non-self structures like environmental factors.  1 
 
1.1.2. Innate and Adaptive Immunity 
The process of a normal immune response against pathogens is a 2-stage immune 
response characterized by the initial defence of components of the innate immunity, 
which is unspecific and triggered by general inherent recognition mechanisms of 
pathogen patterns, followed by an adaptive immune response, where immune cells 
are generated with high specificity against the one disease-causing pathogen. After 
pathogen clearance, some of these cells that specifically recognize this disease-
14 1. Introduction 
 
causing pathogen turn into memory cells to provide long-term immunity against one 
specific microbe.  
 
1.1.3. Humoral and Cell-mediated Immunity 
The two major branches of the adaptive immune system are the humoral immune 
response and the cell-mediated immune response. Depending on the kind of 
invading pathogen, which can be intra- or extracellular, there is preferentially one way 
of immune response triggered. While the cell-mediated immunity is characterized by 
cell-cell interactions, where immune cells like T-cells help killing infected or malignant 
host cells, the humoral immunity is provided by B-cells that upon stimulation with 
antigens and other immune cells differentiate into plasma cells, which secrete 
antibodies with defined specificities. Toxins, pathogens and molecular structures that 
are tagged by antibodies are prone to be erased by the complement system or by 
immune cells like macrophages, which can engulf and digest for example tagged 
bacteria. The most abundant antibody isotype in the blood is IgG. About 60% of IgG 
antibodies are circulating in the body via lymphatic and blood vessels, 40% are 
distributed in extracellular fluid.  1, 2 
 
1.1.4. Reaching Potentially Unlimited Specificity 
B-cells can reach a vast number of specificities against molecular structures with B-
cell receptors (BCR) and antibodies, which are secreted forms of BCR, though they 
have only a limited number of genes. The variable domains, which compose the 
antigen-binding site, are built up of 3 gene segments, the so-called VDJ-genes. 
During the VDJ-recombination event of heavy chains 1 of 40 V (variable) segments, 1 
of 25 D (diversity) and 1 of 6 J (joining) segments are recombined together with the 
corresponding constant domains (Figure 1). Light chains are produced analogue but 
there are no light chain D-segments. This somatic recombination of DNA is carried 
out by RAG (recombination activating gene) enzymes leading to unique VDJ-
recombinations in every B-cell. Another mechanism in fine-tuning the antigen-binding 
specificities is somatic hypermutation, a process where mature B-cells undergo 
mutations in the hypervariable regions of the V(D)J-gene segments. These sites 
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correspond with the complementary determining regions (CDR), which are those 
loops of a BCR or an antibody that directly interacting with the antigenic molecular 
structure. Mechanisms to change the specificity after V(D)J-recombination should 
avoid binding to self-structures.  1 
 
 
 
Figure 1 Somatic V(D)J-recombination of light and heavy chain of an antibody. 1 During 
V(D)J-recombination one V and one J DNA gene segment (light chain) and one V, D and J 
segment (heavy chain) are recombined at DNA level resulting in one recombined V-region 
gene domain. mRNA transcripts containing this V-region gene are spliced together with a 
constant region gene of a certain isotype. Polypeptide chains are assembled to form a 
functional antibody/BCR in the endoplasmatic reticulum.  
 
1.1.5. Autoimmune Diseases - The Immune System is Imbalanced 
Autoimmune diseases are disorders characterized by an adaptive immune response 
directed at self-antigens. Inflammations carried out by immune cells amplify the 
inflammatory signal. Compared to pathogen-caused inflammations self-antigens 
16 1. Introduction 
 
cannot be eliminated easily because of their ubiquitous expression. Sustained 
inflammatory stimuli lead to chronic diseases with self-renewing feedback loops due 
to ongoing expression of the antigen maintaining disease symptoms.  
 
Initially the recombination of gene segments followed by somatic hypermutations 
raises immune cells with potentially unlimited specificities, which also includes 
reactivities against self-structures. But to get rid of these poly- and self-reactive cells 
there are three major checkpoint mechanisms.  3 
Receptor editing in self-reactive precursor B cells in the bone marrow is used by 
combining and testing other V and/or J light chain gene segments. 
Clonal deletion is defined as self antigen-induced death of autoreactive B-cells. 
Programmed cell death called apoptosis throughout the maturation of B-cell can be 
induced at certain developmental checkpoints, if cells display autoreactivity.  
Anergy is another mechanism, where the proliferation of T- or B-cells is suppressed 
due to binding self-structures.  
Autoimmune diseases only develop if one of these safeguards can be overcome due 
selective pressure when challenging pathogens, molecular mimicry of pathogenic 
structures with self-structures or injuries leading to accessibility of self-antigens that 
would not be encountered else by immune cells. Genetic contributions may be a 
major factor for the susceptibility to autoimmune diseases. Mutations in genes that 
are involved in the checkpoint safeguard machinery can be of critical importance.  1 
 
1.1.6. Rheumatoid Arthritis 
Rheumatoid Arthritis is a chronic inflammatory disease that affects 0,5 – 3,0% of the 
Caucasian population. Patients suffer from inflamed joints due to an autoimmune 
response. Disease progression can lead to the erosion of bones and cartilages. 
Consequences are chronic pain and disability of joint function. Though a lot of 
investigations about the mechanisms underlying this disease have resulted in the 
development of new biologics, rheumatoid arthritis still remains a chronic disease 
with feasible relapse. 1, 4 
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Multiple characteristics have been described for rheumatoid arthritis. Immune 
responses of T- and B-cells against certain autoantigens like collagen type II (CII), 
citrullinated peptides (CPP) or IgG!s have been shown. The injection of pathogenic 
IgG antibodies against CII can enhance the development of arthritis in mice, claiming 
an important role of antibodies in this disease.  5, 6 Interestingly, antibodies against 
certain self-structures can be found in many but not every patient.  4 
 
 
1.2. Therapeutic Immunoglobulin G 
1.2.1. IgG Structure 
B-cell receptors (BCR) and antibodies consist of 2 heavy and 2 light chains that are 
each divided into variable and constant domains (Figure 2). Naive B-cells initially 
only express constant regions of heavy chains (CH) of the Cµ and the C" class (IgM 
and IgD). The CH genes are encoded downstream of the rearranged VDJ-region 
segments. Thus, a naive B-cell that has undergone VDJ-recombination expresses 
one VDJ-region assembled to whether Cµ or C" classes which leads to 
transmembrane IgM or IgD of same antigen specificity. If B-cells become stimulated 
by antigens they are able to undergo class switching, which allows them to link their 
VDJ-region to other C-region classes (Figure 3). Class switch recombination 
determines which Ig isotype an activated B-cell will secrete when it terminally 
differentiates into a plasma cell.  1 
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Figure 2 Antibody structure 1 (figure modified). An antibody consists of 2 identical long heavy 
chains containing 1 variable region domain (VH) and 3 constant region (CH) domains. Both 
chains are covalently linked via disulfide bonds (cystin bridges). The 2 shorter light chains 
bind via hydrogen bonds to the heavy chains and consist of 1 VL and 1 CL domain. Grey 
hexagons indicate glycosylation sites in the CH2 domain of C! (IgG).  
 
 
 
Figure 3 Immunoglobulin isotypes. 1 Activated B-cells undergo isotype switching, which 
means that upon cytokine stimulation the Ig heavy chain locus is recombined and the V-
region is assembled with one CH gene. Besides IgA (C"), IgD (C"), IgE (C#) and IgM (Cµ) there 
are 4 isotype subclasses of IgG (C!) genes. Grey hexagons indicate glycosylation sites. Mice 
and humans have homologues CH genes.  
 
 
Roughly 5% of serum antibodies are of IgM subclass. IgM antibodies usually appear 
at elevated levels at the beginning of an infection, because they are besides IgD the 
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first Ig-subclass to be expressed before B-cells undergo class switching. The most 
abundant isotype in the blood of vertebrates like humans and mice is IgG, which 
makes up to 85% of immunoglobulins in the serum.  2  
IgG antibodies are associated with pathogen clearance and toxin neutralization and 
are the primary mediators of protective humoral immunity and inflammation. 7 There 
are 4 different IgG subclasses in humans and mice. When a B-cell becomes 
activated and undergoes isotype switching it might rearrange with one of the 4 
different IgG subclasses 1, which are all functionally different due to different binding 
properties to immune receptors that carry out certain effector functions. 8, 9 Mouse 
IgG2a and IgG2b are considered to have a high pathogenic potential to trigger 
inflammation in autoimmune diseases. 10  
 
 
Human Mouse 
IgG1 IgG2a 
IgG2 IgG3 
IgG3 IgG2b 
IgG4 IgG1 
Table 1 IgG subclass homologues in humans and in mice. Corresponding IgG subclasses 
between species are shown due to sequence homologies. Their abundance in blood serum 
and their effector functions though differ between species. Numbering of human and mouse 
IgG subclasses were done according to the blood serum levels. IgG1 is the most abundant 
isotype in the serum of one species.  
 
 
1.2.2. Fc-Glycan Structure 
Cleavage of antibodies with a proteolytic enzyme called papain leads to peptide 
fragments. Papain cleaves antibodies in the hinge region between the CH1 and the 
CH2 domain releasing the 2 antigen binding arms (Fab, fragment antigen binding) 
and the CH effector region dimer (Fc, fragment crystallizable) (Figure 2).
 1 In IgG 
antibodies this Fc-region contains the only glycosylation site at each heavy chain 
asparagine 297 (Asn297) having an N-linked biantennary oligosaccharide attached 
(Figure 4). 11, 12 These oligosaccharide glycans are sugar chains that point to each 
other influencing the conformation of the Fc effector region. IgG Fc-glycans are 
crucially necessary for their effector function. Specific cleavage of IgG Fc-glycans by 
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the bacterial enzyme endoglycosidase (EndoS) completely abrogates cytotoxicity of 
IgG antibodies.  13, 14, 15  
Different Fc-glycan structures have been associated with different effector functions 
of IgG antibodies. 14, 16 Even monoclonal antibodies produced by one hybridoma B-
cell have different Fc-glycosylation pattern. There are 4 prominent Fc-glycan isoforms 
associated with effector functions. Short Fc-glycans have biantennary terminal N-
acetylglucosamine, which can both be elongated with galactose and may terminate 
with sialic acid (Figure 4).  12, 17 
 
 
 
 
 
Figure 4 Fc-glycan structures. Primary N-acetylglucosamine is attached to the Asn297 of 
each heavy chain in the CH2 domain. Depending on the terminal sugar this Fc-core 
oligosaccharide is associated with different effector functions. G0, G1 and G2 isoforms have 
no, 1 or 2 terminal galactoses. S1 and S2 isoforms have 1 or 2 terminal sialic acids. About 
10% - 15% of serum IgG!s from healthy donors harbour Fc-glycans with terminal sialic acid 12, 
which provide antiinflammatory properties to antibodies.  
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1.2.3. Fc-glycosylation in Autoimmune Diseases 
It has already been reported in the 1980!s that patients with rheumatoid arthritis have 
serum IgG antibodies with altered Fc-glycan structures compared to healthy 
individuals. Interestingly, whole blood serum IgG!s in patients with chronic 
rheumatoid arthritis have shorter Fc-glycans with more than 60% of IgG!s harbouring 
G0 glycans (Figure 4) and any glycans having terminal sialic acid. In healthy 
individuals up to 15% of serum IgG!s have oligosaccharides with terminal sialic acid 
and most of the glycans are in the G1 or G2 isoform. Patients with rheumatoid 
arthritis that turned into remission back to a healthier state express again serum IgGs 
with predominantly longer Fc-glycan chains.  
These findings were first indications that Fc-glycosylation patterns may have a strong 
influence on the function of IgG!s in chronic inflammatory diseases.  16, 18 
 
 
 
Figure 5 Mass spectroscopic (MALDI-TOF) analysis of IgG Fc-glycans. 12, 16 Each peak in the 
diagram represents the amount of Fc-glycans of a certain isoform. In rheumatoid arthritis 
there is a prominent peak at about 2650 m/z, which means compared to the other peaks, that 
most glycans accelerated in the mass spectroscopic analysis are in the G0 glycoform having 
no galactose and no terminal sialic acid. Only healthy individuals display Fc-glycans with 
terminal sialic acid (about 3250m/z), which therefore became attributed to have 
antiinflammatory effector properties.  
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1.2.4. Intravenous Immunoglobulin G (IVIG) Therapy 
Intravenously injected immunoglobulin G (IVIG) is an approved therapeutic containing 
pooled serum IgG of all subclasses from up to 10 000 healthy donors. IVIG has 
turned out to be a potent tool not only to treat immunodeficient patients but also for 
patients with autoimmune diseases. High dose IVIG shift the antibody response in 
the blood towards a healthy state but mechanisms of action have still not been solved 
completely. 
In 2008 Anthony et al. recapitulated the antiinflammatory activity of IVIG with 
sialylated Fc portions. 19 IgG Fc dimers without Fab fragments could provide the same 
benefit as full-length IVIG antibodies and this effect was only due to terminal sialic 
acid on the Fc-glycan. Fc-fragments without terminal sialic acid showed no beneficial 
efficacy in autoimmune disease models.  19, 20  
Rheumatoid arthritis is an autoimmune disorder where alterations in the Fc-
glycosylation patterns of IgG antibodies can be observed (Figure 5).  21 Several 
cases of IVIG therapy provided benefit to the patients with rheumatoid arthritis, 
probably due to a shift of the Fc-glycan isotype distribution of serum IgGs back to a 
healthy glycosylation state with terminal sialic acid. However, studies have proved 
therapeutic effects of IVIG in rheumatoid arthritis treatment, but detailed models of 
the efficacy are lacking.  
 
1.2.5. Contraindications of IVIG 
Thus Fc sialic acid is a key sugar that provides IgG antibodies with antiinflammatory 
effects and production of antibodies without sialylated Fc-glycans may provide a shift 
from a healthy steady state to inflammation.  
But there are several disadvantages in the treatment of patients with IVIG. It has to 
be given in very high doses of around 2g/kg per month to eclipse the intrinsic IgG 
effects. Due to the production procedure IVIG is a very cost intensive therapy. 
Frequently side effects like headache and fatigue are reported. Beyond, IVIG 
provides a systemic effect and even the transfer of allergies due to IgG!s from donors 
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that target allergens have been reported. So scientists strive for more specific options 
exploiting the beneficial effects of IVIG. 7, 19, 22, 23, 24 
 
1.2.6. How IVIG Work 
IgG antibodies can bind components of the complement system, but they also 
interact with immune cells via Fc!-receptors. There are several different activating 
Fc!-receptors, which upon crosslinking after binding to the Fc-portions of IgG!s trigger 
proinflammatory signalling pathways. This leads to the expression of proinflammatory 
cytokines such as TNF-", IL-1 and IL17, a prominent cytokine in autoimmune 
diseases. There is only one inhibitory Fc!-receptor on immune cells, the Fc!-receptor 
II B (Fc!RIIB). 25 Activation of the Fc!RIIB upon binding of IgGs starts a signalling 
cascade that leads to a feedback loop with enhanced expression of Fc!RIIB. The 
ratio of activating to inhibitory signalling decreases and the threshold to trigger 
immune responses rises. This results in the protection of self-structures from further 
threat by inflammation. 
IgG antibody subclasses show different affinities to activating and inhibitory Fc!-
receptors with mouse IgG1 showing the lowest activating to inhibiting ratio. 
Sialylation of IgG antibodies reduced their cytotoxicity due to lowered affinities of 
IgGs to Fc!-receptors. This mechanism is supposed to ensure steady-state serum 
IgGs to maintain calm. But when challenged with pathogenic antigens the antigen-
specific IgG!s can be switched to a population of reduced sialic acid to provide 
inflammatory effector functions for proper pathogen clearance.  9, 20 
It has been shown that the antiinflammatory effect of IVIG can be translated by 
splenic marginal zone macrophages via a C-type lectin receptor called SIGN-R1 
(specific ICAM-3 grabbin non-integrin related 1) in mice. 22 This receptor is only 
expressed on splenic marginal zone macrophages and is crucial for the 
antiinflammatory function of IVIG because upon binding of sialylated Fc!s, marginal 
zone macrophages induce upregulation of the inhibitory Fc!RIIB on effector 
macrophages, so the ratio of inhibitory to activating Fc!-receptors increases. The 
human homologue DC-SIGN is not expressed on macrophages but dentritic cells. 
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Therefore results concerning the activity of this receptor must be translated to 
humans with care.  26 
There are only few publications suggesting any functional pathway on how sialylated 
antibodies act at sites of inflammation except of studies showing that sialylated IgGs 
have reduced affinities to Fc!-receptors. The influence of sialylated IgG!s on other 
immune cells like T-cells is currently subject of investigations. 27  28  
Recent findings have described the interference of IVIG in antigen presentation and 
therefore indirectly influencing the activation of T- cells.  28 IVIG-Fc binding reduced 
the ability of antigen-presenting cells to present antigens via MHC class II to CD4+ T-
cells, which did not become activated. This effect of IVIG was shown to be 
independent of the inhibitory Fc!RIIB. Binding of IVIG-Fc to antigen-presenting cells 
occurred via activating Fc!-receptors.  
 
 
1.2.7. Sialylated Antigen-specific Antibodies 
IVIG has a systemic shut down effect on the immune system, but if there is a way to 
direct this anti-inflammatory property of sialylated IgGs to interfere antigen-
specifically in the inflammatory response this must lead to the antigen-specific shut 
down of inflammatory signals. Inhibitory effector functions of sialylated Fc!s combined 
with antigen-specificity of the Fab fragment may lead to a precise immune regulation 
without systemic side effects.  
Anti-CII antibodies have been shown to bind CII in mouse joints in vivo and to induce 
severe arthritis,  5, 6, 29 therefore suggesting that sialylated anti-CII IgGs antigen-
specifically target CII in the joints. Interference of sialylated CII-specific IgGs in 
antigen presentation and therefore in T-cell activation is one proposed mechanism 
leading to inhibitory effects in the development of arthritis. 
However, we did not know if any other receptor (probably related to SIGN-R1) than 
the inhibitory Fc!RIIB expressed on immune cells leads to immunosuppressive 
signalling or if even activating Fc!-receptors of antigen-presenting cells translate 
antibody binding into antiinflammatory responses, like suggested by Aubin et al.  28  
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The Fc!RIIB is crucial in counterbalancing autoimmunogenic stimuli. 30 Thus, in 
Fc!RIIB-/- knock out mice beneficial effects of sialylated CII-specific antibodies must 
elicit other regulatory mechanisms. 
 
 
1.2.8. Treat Autoimmune Disease With Sialylated IgG’s 
To examine if we can use the antiinflammatory effect of sialylated IgG!s in an 
antigen-specific way, we chose an autoimmune disease model with a defined 
immune response. A mouse model for rheumatoid arthritis is chicken collagen-
induced arthritis (CIA), where mice are immunized with heterologues chicken 
collagen type II (CII). The initiation of an immune response harbours the risk of a 
cross-reaction with self-CII, which is a component of the synovial fluid in joints. If 
adjuvant stimulation is strong enough, tolerance of self-CII can be broken and an 
excessive immune response with high potential for cross-reaction with self 
establishes.  
In CIA there is a defined antigen (CII) that can be targeted by CII-specific IgG 
antibodies. Usually these antibodies promote the disease. 6 So we glycosylated the 
Fc-glycan of the anti-CII IgG!s by attaching galactose and terminal sialic acid to the 
oligosaccharide chain. These sialylated antibodies targeted chicken and mouse CII to 
direct their antiinflammatory effects to foreign and self CII. 
The idea was to prevent mice from the development of arthritis due to inhibiting an 
immune reaction against CII by applying therapeutic antibodies (sialylated anti-CII 
IgG1) before the immunization with chicken CII. We hypothesized that upon the 
trigger of an immune response against CII, the antigen is already protected by 
sialylated IgG!s that reflect a normal steady-state sialylation, which prevents the mice 
from the development of inflammatory immune responses against chicken and self- 
CII and thereby of arthritis.  
 
IgG1 antibodies were used, because it has been shown that they have less cytotoxic 
activity compared to IgG2a or IgG2b subclasses. 9, 10 Additionally, we investigated the 
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effect of sialylated IgG1 antibodies in Fc!RIIB-/- mice to analyze the role of the 
inhibitory Fc!RIIB. 
 
 
 
Figure 6 Therapeutic anti-CII IgG antibodies are sialylated to induce tolerance to chicken 
and self-CII and to inhibit joint swelling.  
 
 
1.2.9. Glycosylation of Therapeutic Antibodies for Clinical Applications 
Since the 1990!s therapeutic IgG antibodies have become the fastest growing class 
of human therapeutics and the second largest class of drugs after vaccines. IgG 
antibodies for passive immunization to clear pathogens as well as for the treatment of 
chronic inflammatory diseases or tumors have been approved to the market. Recent 
findings have suggested the IgG Fc-glycan to have strong modulating effects. E.g. if 
core fucose is removed, antibodies display increased cytotoxic effector functions. 31 
Sialylation of recombinant proteins has been carried out by industry to increase the 
half-live of biologics, but recent findings propose that sialylation of IgG Fc-glycans 
reduces their ability to engage Fc!-receptors and even provide tolerance to the 
antigenic structures. Fc-glycans with terminal sialic acid have therefore become a 
target of autoimmune disease research. Self-antigen-specific sialylated IgG with 
antiinflammatory activity are a potent future tool to inhibit inflammatory diseases like 
rheumatoid arthritis.   11, 14, 15, 32, 33  
 
 
 
  
2. Aim 
Therapeutic antibodies have become an increasingly emerging market. Antibody 
based biologics have been developed to targed and clear pathogen-associated 
structures and malignant cells as well as inflammatory cytokines in chronic 
inflammatory disease. Recent findings suggested that the effector function of IgG 
antibodies can be modified upon structural changes of their Fc-glycan. Terminal sialic 
acid on this Fc-glycan gives IgG antibodies antiinflammatory properties providing 
switch mechanisms between a healthy steady-state with tolerance against specific 
antigens and activating effector functions.  
We used the chicken collagen-induced arthritis mouse model, which reflects a 
rheumatoid arthritis-like phenotype, as autoimmune disease model with defined 
immune response against one self-antigen (collagen type II).  
The aim of this project was to newly design self-antigen-specific IgG antibodies with 
antiinflammatory activity due to Fc-sialylation to prevent the development of arthritis 
in mice. Our goal was to develop a novel therapeutic approach to treat autoimmune 
diseases - not by blocking proinflammatory cytokines - but to directly target the 
immunogenic self-antigen (collagen type II) with sialylated IgG antibodies to enhance 
tolerance. Antigen-specific application should lead to individualized therapies 
avoiding the systemic and negative effects of IVIG and could be administered at 
much lower dose to prevent from side effects. 
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3. Materials and Methods 
3.1. Expression Vector Cloning 
3.1.1. Anti-Collagen Type II Antibody Sequences 
We used sequences of antibodies specific for collagen type II (CII) of different 
species that have been described in the literature. However, articles describing 
nucleotide sequences of the variable region (V-region) of anti-CII IgG!s usually focus 
on the complementary determining region (CDR) sequences, which are of main 
interest when studying the interaction of antibodies with antigens. To obtain the full-
length nucleotide sequences of the V(D)J-regions of IgH (heavy) and IgL (light) chain 
genes, which were necessary for cloning, we completed V(D)J-region sequences of 
anti-CII antibodies 34, 35, 36 (Table 2) with their corresponding germ line gene 
sequences that were determined by IgBLAST comparison with GenBank database 
(http://www.ncbi.nlm.nih.gov/igblast/) and sequences of the IMGT database 
(http://imgt.cines.fr) 36 (Table 3). Additionally we corrected mismatches between the 
anti-CII IgH and IgL chain sequences and their germ line genes that appeared 
upstream of the CDR1. Sequencing errors could have been the reason for these 
mismatches. In case of doubt we used the germ line sequence.  
If IgH or IgL chains were described in part as amino acid sequence in the literature, 36 
the triplet codon of the corresponding germ line gene was corrected by single base 
exchange according to the germ line gene segment. To ensure segregation of the 
antibody chains we added a leader sequence (GenBank accession number 
DQ407610) also containing an AgeI restriction site for cloning. At the end of the 
heavy chain VDJ DNA sequence a SalI restriction site was introduced to later 
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combine the VDJ sequence with the constant murine IgH chain in frame. Accordingly 
at the end of the light chain VJ DNA sequence a BsiWI restriction site was introduced 
to later combine the VJ sequence with the constant murine Ig$ sequence in frame. 
The final anti-CII antibody sequences (Table 4) of the IgH and IgL chain V-regions 
were ordered at MrGene (https://mrgene.com). 
 
 
Antibody IgH IgL Mouse Strain 
aCII 1-5  35 U69538 U69539 DBA/1J 
M2139 36 Z72462 Z72463 DBA/1 
ACC1 36 EU159566 EU159567 B10.RIII.Cia5 
CIIC1-GG 36 Z72441 Z72442 DBA/1 
CIIC1-E 36 Z72441 Z72442 DBA/1 
Table 2 GenBank accession numbers. Nucleotide sequences of the V(D)J-regions of heavy 
and light chains of anti-mouse CII antibodies used as templates for assembling our antibody 
sequences. 
 
 
Antibody Orig. Isotype V-gene D-gene J-gene V-gene J-gene 
aCII 1-5  35 IgG2a J558.45 DFL16.1 JH2 12-44 JK1 
M2139 36 IgG2b J558.45 DSP2.8 JH2 21-1 JK2 
ACC1 36 IgG2c J606.4.82 DST4.2 JH2 21-2 JK2 
CIIC1-GG 36 IgG2a J558.40 DST4.2 JH3 21-5 JK2 
CIIC1-E 36 Ig
 h
e
a
v
y
 c
h
a
in
 
IgG2a J558.40 DST4.2 JH3  I
g
 k
a
p
p
a
 c
h
a
in
 
21-5 JK2 
Table 3 Corresponding germ line VDJ IgH gene segments and VJ IgL kappa gene segments 
used to fill up incomplete sequences. Mutations far upstream of the CDR1 region have been 
reverted according to their germ line V-genes. Germ line gene segments were determined by 
IgBLAST and IMGT database. 
 
 
3.1.2. Expression Vector 
To co-express the IgH and the IgL chain of each antibody in cell culture we used 
expression vectors for murine IgG1 heavy chains (mIgG1) and murine kappa light 
chains (Ig$). 3, 37, 38 The vectors (Figure 7; GenBank accession number DQ407610) 
were a kind gift of Dr. Hedda Wardemann (Max-Planck-Institute for Infection Biology, 
Berlin).  
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Upstream of the mIgG1 and the mIg$ sequences there is a multiple cloning sites 
(MCS) containing AgeI and SalI  (IgG1) and AgeI and BsiWI (Ig$) restriction sites to 
insert the V(D)J region sequences. The human cytomegalovirus (HCMV) promoter 
provides a strong transcriptional activity. Selection occurs via an ampicillin resistance 
cassette. 
 
 
 
Figure 7 Expression vector maps. 38 The human cytomegalovirus promoter is followed by a 
leader sequence, a MCS for inserting the V gene sequences and an IgG1 (!1 heavy chain) or 
an Ig$ ($ light chain) constant region. The eukaryotic expression vectors are promoted in 
bacterial clones based on ampicillin resistance. 
 
 
3.1.3. Restriction Digest 
The VDJ region sequences of the IgH chains were cut out of the vector backbone 
delivered by MrGene with AgeI and SalI restriction enzymes. The VJ regions of the 
IgL chains were cut with AgeI and BsiWI (all enzymes by NEB – New England 
Biolabs). IgG1 heavy chain and Ig$ light chain expression vectors were digested 
analogous to create sticky DNA ends, where the V(D)J sequences could be inserted 
37, 38 The reaction conditions were set up according to the manufacturers instructions 
(NEB). Just in brief, 3µg DNA were digested with 3U restriction enzyme in 30µl total 
reaction volume containing 3µl of the proper 10x enzyme buffer (AgeI and SalI (IgH) 
in NEB-4 buffer, AgeI and BsiWI (IgL) in NEB-1 buffer). IgH (AgeI, SalI) sequences 
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were double digested at 37°C for 1h. Ig$ sequences were digested sequentially. After 
AgeI digest for 1h at 37°C, 3U BsiWI were added and temperature was raised to 
55°C for 1h.  
 
3.1.4. Fragment Purification 
Prior to ligation the digested V-region fragments were seperated from the vector 
backbones on a 0,9% agarose gel (1xTAE buffer (Tris-acetate-EDTA), 1µl ethidium 
bromide per 20ml agarose gel; Orange G loading dye) for 30 minutes at 140V. 
Fragments were cut out of the gel with a scalpel and purified with 
NucleoSpin® Extract II kit (Macherey-Nagel) according to manufacturers instructions.  
 
3.1.5. Ligation 
Reaction volumes for ligation of the V-region fragments into expression vector 
backbones were calculated with GENtle software. The total reaction volume was 10µl 
containing 2µl 5x T4 DNA-Ligase reaction buffer (Invitrogen). 100ng DNA with a 
molar insert to vector ratio of 3:1 was ligated by 1U of T4 DNA-Ligase (Invitrogen) for 
20 minutes at room temperature.  
  
3.1.6. Transformation 
Competent E. coli DH10B bacteria (Clontech) were thawed on ice and incubated with 
100ng ligated DNA for 5 minutes on ice. The transfer of the expression vector into the 
bacterial cells – called transformation – was carried out for 30 seconds on 42°C. After 
1 minute on ice 250µl pre-warmed SOC-medium were added and transformed 
bacteria recovered for 30 minutes shaking at 37°C. 100µl transformed bacteria were 
plated onto lysogeny broth (LB) ampicillin (100µg/ml) plates and incubated over night 
at 37°C. 
The antibiotic ampicillin was used to select for ampicillin resistant clones carrying our 
expression plasmid with an ampicillin resistance cassette, which expresses the 
enzyme beta-lactamase to cleave cell wall synthesis inhibiting ampicillin in the 
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medium. Only bacteria expressing beta-lactamase could proliferate to from colonies 
in the presence of ampicillin.  
 
3.1.7. Plasmid Preparation 
Colony forming units (CFU) of single bacterial clones carrying the transformed 
plasmid were picked and grown in 4ml liquid LB-medium over night shaking at 37°C. 
Preparation of plasmids (NucleoSpin® Plasmid, NucleoBond® Xtra Maxi Plus, all by 
Macherey-Nagel) was done due to instruction guidelines. Just in brief, after 
centrifugation the cell pellets were resuspended and cells were lysed in an 
SDS/alkaline buffer to set the plasmids free. Genomic DNA, which is attached to the 
bacterial cell membrane, is washed away after neutralization. Clarified lysates are 
transferred to a silica membrane where plasmid DNA keeps bound throughout 
several washing steps until elution with 50µl elution buffer (5mM Tris/HCl, pH8.5). 
 
3.1.8. Sequencing 
To screen V-region inserts of the IgG1 and Ig$ chains for correct insertion into the 
vector and for mutations we delivered the final constructs containing the aCII-
antibody IgH and IgL chains to MWG (http://www.eurofinsdna.com/de/) for 
sequencing. Primers 37 were binding upstream of the insert in the leader sequence 
(Ab-sense) of the aCII-antibody chains and in the respective murine IgG and murine 
Ig$ C-region.  
 
 
Insert check  Primer name  5!-3! sequence 
 5# Absense 37 GCTTCGTTAGAACGCGGCTAC 
 3# IgG (internal) 37  GTTCGGGGAAGTAGTCCTTGAC 
 3# C$ 494 37  GTGCTGTCCTTGCTGTCCTGCT 
Table 4 Primer sequences for the insert screen. 5! Absense binds in the leader. 3! primers 
bind in the C-region of IgH (IgG internal) and IgL (C$ 494). Sequencing products reveal 
mutations and correct insertion of the V(D)J-region fragment.  
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3.2. Antibody Expression 
3.2.1. Cell Culture 
For the expression of the anti-CII mouse antibodies we used an immortalized human 
cell line. Those human embryonic kidney 293T (HEK293T) cells were cultured on 
15cm tissue plates (Greiner) in 25ml Dulbeccos modified eagle medium (DMEM + 
GlutaMax%-I; Gibco) containing 10% fetal calf serum (FCS) and 10ml/L 
penicillin/streptomycin (by PAA) and incubated at 37°C and 5% CO2. Optimal growing 
condition could be achieved when passaging the cells twice a week at a confluency 
of 80%. The cells were trypsinised with 3ml of trypsin-EDTA (PAA) after removal of 
the medium and washing with 15ml 1xPBS and distributed to new culture dishes at a 
ratio of 1:3 – 1:10. 
 
3.2.2. Transfection 
Best transfection efficiency could be achieved at a cell confluency of about 70% at 
the time of transfection. Cells should be in exponential growth phase (log phase) with 
least contact growth inhibition. 
Cell culture dishes were washed with 1xPBS before adding transfection medium 
containing 22ml DMEM per plate with 2,5% primatone in PBS (Kerry Primatone 
RL/UF 5X59057) cell culture additives and 10ml/L penicillin/streptomycin (PAA) but 
no FCS to avoid IgG contamination. 10µg heavy chain and 10µg light chain plasmid 
DNA (per plate) are vortexed for 30s with 0,6µg/µl of branched polyethylenimine (PEI, 
Sigma 408727) in a final volume of 3,000µl PBS. Positively charged PEI forms 
complexes with negatively charged DNA, which can be taken up by the cells when 
the transfection mix is carefully added to the transfection medium on the cell culture 
dish. The cell medium supernatant was harvested after 4-6 days of incubation at 
37°C and 5% CO2. 
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3.2.3. Antibody Purification 
Harvested supernatant containing the secreted antibodies was centrifuged 10min at 
4000rpm to remove cell contamination followed by sterile filtration in a Stericup®  
(Millipore). Clear sterile supernatant was run through a Protein G Sepharose® (GE 
Healthcare) column. Binding to protein-G in the column retained the antibodies. 
Elution was performed by adding 5x the column bed volume of 0,1 glycin buffer 
(pH3). The fractions were collected and neutralized with 1/20 of the elution volume of 
1M Tris/HCl buffer (pH 8,5). Antibody concentration, which was usually high in 
fractions 2 and 3, was determined by photometric analysis at a wavelength of 280nm 
(NanoDrop). 
Before storage at -80°C the antibody solution was dialysed over night against 1xPBS.  
 
3.2.4. SDS-PAGE 
The expression of both, antibody heavy and light chain in the HEK293T cells was 
verified via denaturating polyacrylamid gel electrophoresis (PAGE). 10µg of each 
purified antibody sample mixed with protein loading buffer was heated for 10min at 
94°C. Loading buffer contained sodium dodecyl sulfate (SDS), which is an 
amphiphilic detergent where the non-polar carbohydrate chain (C-12) wraps around 
the heat denatured protein backbone. The anionic sulfate head of the molecule 
provides charge to the SDS-protein complex. The larger a protein the more SDS 
molecules can attach, which provides every protein chain with the same mass to 
charge ratio of 1,4µg SDS per 1µg protein. Protein migration in an electric field 
occurs due to size in a polyacrylamid gel. The intrinsic charge of the protein becomes 
negligible. Loading buffer (0,25M Tris-HCl) additionally contains glycerin to give the 
samples more density for optimal loading conditions. &-mercaptoethanol reduces 
disulfide bridges for complete denaturation of the protein. Bromphenol blue is used 
as a tracking dye.  
A protein ladder (Kaleidoscope; BioRad) with recombinant prokaryotic proteins of 
known size was used as molecular weight marker.  
10% AA (acrylamid/bisacrylamid) resolving gel was made with 5,9ml H2O, 5,0ml 
acryl-bisacrylamide mix (30% AA), 3,8ml 1,5M Tris (pH 8,8) and 150µl SDS. 150µl 
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ammonium persulfate (10% APS) initiates gel formation when finally 6µl of TEMED 
are added to start polymerization.  
5% AA stacking gel was formed by mixing 5,5ml H2O, 1,3ml AA (30%), 1ml 1,5M Tris 
(pH 6,8) and 80µl SDS (10%). Polymerization was started with 80µl APS (10%) and 
8µl TEMED.  
The gel was run at 140V for 3h.  
 
3.2.5. Enzymatic Glycosylation 
Enzymatic in vitro glycosylation was performed in a two-step procedure by first 
galactosylating and second sialylating the antibodies 19. Buffer exchange of 5mg of 
one antibody at a concentration of 1mg/ml was carried out in a 5ml Amicon® Ultra-4 
Centrifugal Filter Units (50kDa size exclusion; Millipore) according to manufacturer!s 
instruction. MOPS buffer (50mM, pH 7,2) was carefully(!) added drop wise after 
centrifugation steps until no PBS buffer was left. Phosphate ions of PBS would 
precipitate brown after addition of mangan.  
1M MnCl2 (in H2O) was added to a final concentration of 20mM. Mangan is a 
necessary cofactor of the &-1,4-galactosyltransferase [5mU/µl] (Sigma 48279), which 
was added to a final concentration of 75mU/ml with 5,3mg/ml UDP-Gal [0,25mg/µl]. 
The galactosylation was run for 48h at 37°C shaking. White precipitates, which 
indicated enzymatic activity, were removed via centrifugation and reaction buffer was 
exchanged in an Amicon® Centrifugation Filter Unit (Millipore) to 50mM MES (pH6) 
containing 10mM of 1M MnCl2 and 0,5mg CMP-Sial [25µg/µl]. After addition of 50mU 
of &-1,6-sialyltransferase [1,43mU/µl] (St6Gal1, Calbiochem 566223), sialylation was 
carried out for 48h at 37°C shaking. Finally antibody solutions were washed with 
100mM NaCl2 to remove any mangan and buffered in 1xPBS. Antibody concentration 
after galactosylation and sialylation were determined by photometric measurement at 
280nm (NanoDrop).  
Efficiency of enzymatic glycosylation and antibody Fc-N-glycosylation pattern were 
analysed by MALDI-TOF. Reactivity pattern of antibodies were verified via ELISA. 
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3.2.6. MALDI-TOF Analysis 
MALDI-TOF mass spectrometry was used to resolve Fc-oligosaccharide structures. 
IgG antibody samples were digested with endoglycosidase S (EndoS) purified from 
Streptococcus pyogenes. EndoS specifically cleaves the N-linked oligosaccharide at 
the Fc-fragment exclusively from IgG antibodies between the first and second N-
acetylglucosamine (GlcNAc). Cleaved oligosaccharides were purified by solid phase 
extraction using reversed-phase C18 and graphitized carbon columns (Alltech, 
Deerfield, IL). Oligosaccharide samples were permethylated according to standard 
protocols and further investigated by MALDI-TOF mass spectrometry. Spectra were 
recorded on an Ultraflex III mass spectrometer (Bruker Daltonics) equipped with a 
Smartbeam laser. Calibration was performed on a glucose ladder and DHB was used 
as a matrix. Spectra were recorded in reflector positive ionization mode and mass 
spectra from 3000 laser shots were accumulated.  
 
3.2.7. Enzyme-linked Immunosorbant Assay (ELISA) 
The reactivity pattern of the anti-CII antibodies was determined via reactivity ELISA. 
Collagen type II [2mg/ml solubilized in 0,05M acetic acid over night at 4°C (better 
would be 0,01M acetic acid)] of bovine, chicken, human and mouse origin was 
coated at 2µg/ml (gelatine, dsDNA, ssDNA, insulin and LPS at 1µg/ml) in 100µl per 
well on a high binding microtiter 96-well plate over night at 4°C. After 3x washing 
steps with ddH2O, free antigen binding sites were blocked for 1h at room temperature 
with 200µl/well with blocking solution (50mM Tris pH8, 1mM EDTA, 140mM NaCl2, 
0,02% Tween®20, 1% w/v BSA). 100µl of anti-CII antibody samples [1-10µg/ml] and 
3-7 serial 1:3 dilutions of these samples in blocking solution were loaded to the 
microtiter plate after removing blocking solution. Binding of the antibodies to the CII 
occurred during 1h of incubation at room temperature and after another 3 washing 
steps with ddH2O. Another 3 washing steps were followed by 1h incubation at room 
temperature with a horseradish peroxidase (HRP) coupled goat antibody against the 
murine anti-CII-antibody isotype. (IgG1, IgG2a, IgG2b, IgG3, Ig-Fc, IgM or IgA)  3x 
washing was finally followed by a 1-10min incubation of the samples with 100µl TMB 
(BD). Intensity of the TMB colorant that is cleaved by the HRP of the secondary 
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antibody is a direct measurement of the amount of primary antibody bound to CII. 
The reaction was stopped by adding 100µl 1M H2SO4. Analysis of the colour intensity 
was done with a microplate reader at 450nm.  
 
To analyse different isotypes of serum immunoglobulins from arthritic and non-
arthritic mice of different treatment groups via serum ELISA, the same ELISA setup 
was used as discribed above. Coating half of the wells of one microtiter plate with 
mCII and the other half with chCII. Serum (1:200 in PBS) was added and bound 
antibodies were detected on the whole plate with a secondary antibody (HRP-
coupled) against one specific isotype (e.g. IgG1, IgM, ...). Analysis of the isotype 
distribution in the different groups was performed as described above according to 
the colorant intensity in each sample.  
 
 
 
3.3. Collagen-Induced Arthritis Mouse Model 
3.3.1. Mice  
The induction of autoimmune diseases like collagen-induced arthritis is commonly 
elicited in genetically susceptible mouse strains like DBA/1 mice. Susceptibility is 
restricted by the class II molecules of the MHC haplotype H-2q and H-2r. 39, 40 
Nevertheless C57BL/6 (Black 6) mice, which were usually regarded as being 
resistant to collagen-induced arthritis, became a target of studying autoimmune 
diseases, because most genetically modified mouse strains are on a C57BL/6 
background (H-2b) and recent publications have provided protocols for reproducibly 
induce arthritis in H-2b haplotypes. 40, 41 
It has been shown that Fc!RIIB-/- knock-out mice on C57BL/6 background are more 
susceptible to autoimmune disease. 30 Genotypes were determined by PCR on tail 
DNA as described previously. 10 Exclusively male Fc!RIIB-/- mice bred in the DRFZ 
mouse facility Marienfelde were used for the treatment of CIA. Mice were bred and 
maintained in accordance with federal laws and institutional guidelines.  
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3.3.2. Reagent Setup 
Bovine collagen type II (bCII) is commonly used to induce CIA in susceptible mouse 
strains. To reproducibly induce CIA in more autoimmune resistant mice harbouring 
the H-2b MHC haplotype, we used chicken collagen type II (chCII, Sigma), which was 
dissolved over night at 4°C to 2mg/ml in 0,05M acetic acid.  
1vial (100mg) grinded Mycobacterium tuberculosis (H37Ra, Difco Laboratories) was 
added to 25ml Complete Freund!s adjuvants (CFA, Sigma) to increase H37Ra 
content from 1mg/ml to 5mg/ml. Effective immunization with sufficient amount of M. 
tuberculosis as immunogenic stimulus is necessary to overcome tolerance in H-2b 
haplotypes. 40  
 
3.3.3. Collagen-Induced Arthritis 
To finally have 100µl of CFA/chCII immunization mixture per mouse 100µl CFA 
(5mg/ml H37Ra) was vortexed with an equal volume (100µl) chCII [2mg/ml] in a 15ml 
tube (Greiner) and about 800µl of this immunization mixture were aliquoted to 1,5ml 
tubes (Eppendorf). chCII was thaw and handled on ice to avoid denaturation. For 
application it is critical that the emulsion is thick enough not to drip out of the tube 
when inverted  41, so we homogenized the immunization emulsion in the 1,5ml tubes 
with 2x4 short burst using a sonicator at 70% intensity to avoid heating and 
denaturation of the CII. The emulsion was collected with a 19G needle in a 1ml 
syringe. To avoid bubbles the syringes were inverted and tipped strongly at the 
bench edge to collect bubbles at the top, which were then pumped out of the syringe.  
2x50µl of the immunization emulsion were injected per mouse right and left up the 
base of the tail sub cutanously. 41 A booster injection was given 14 or 21 days 
analogue to the immunization but at more anterior site. C57Bl/6 mice were 
immunized a second time with an emulsion containing CFA (5mg/ml H37Ra) 39. RIIB-/- 
mice were boosted with an emulsion containing IFA (Incomplete Freund!s Adjuvant, 
Sigma) instead of CFA.  
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3.3.4. Clinical Assessment of Arthritis 
Clinical assessment of arthritic paws was done according to standard protocols. 40, 41 
Limb swelling of all animals was monitored 3x a week. The clinical score was 
assessed by scoring each limb of a mouse from 0 (healthy) to 3 (severe swelling of 
digits, paw and ankle). The maximum score per mouse is 12. The mean clinical score 
was calculated by including all animals – even healthy ones - of one group. Arthritis 
incidence was considered when at least on limb of a mouse was clinically scored 1.  
 
 
 
Figure 8 Clinical scores of C57BL/6 mice with CIA are assessed empirically. 41 Healthy paws 
(a) show no abnormal swelling, redness, contact sensitivity and motor activity alterations. 
The onset of arthritis with swelling of whether digits, paw or ankle is scored with 1 (a). 
Redness of paws must not be confused with the onset of arthritis. Pronounced limb swelling 
is score with 2 (c). Severe balloon-like whole paw swelling (ankylosis) is diagnosed with the 
maximum score of 3 (d).  
 
 
3.3.5. Serum  
To examine antibody levels and isotype distribution in the blood of arthritic mice, 
200µl blood were collected in a serum collection centrifugation tube by carefully using 
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a scalpel to cut into one tail vein. Tubes were centrifuged at 6000rpm for 10min. 
Serum was transferred to a 1,5ml tube and stored at -80°C. 
 
3.3.6. Statistical Analysis 
Statistical analyses were done with Prism 4 (GraphPad Software). P-values were 
calculated using Student!s t test: *P < 0.05, **P < 0.01 and ***P < 0.001. 
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4. Results 
 
4.1. Expression Vector Cloning 
4.1.1. Antibody Design 
For high quantity cell culture production of anti-CII antibodies we constructed the 
heavy and light chain V(D)J-region sequences (described in 3.1.1.) based on 
published data to clone them into eukaryotic murine IgG1 heavy chain and kappa 
light chain expression vectors. The final V-region sequences are shown for heavy 
chains in Table 5, for light chains in Table 6. They were ordered at MrGene and 
used for further cloning.  
The full length open reading frame (ORF) to be transcribed into the endoplasmatic 
reticulum (ER) for secretion is listed for the aCII 1-5 heavy chain IgG1 vector in Table 
7, for the aCII 1-5 kappa light chain vector in Table 8. The leader contains the 
nuclear export sequence that guides the transcribed mRNA to the rough ER where 
the polypeptide chain is directly translated into the ER. Before secretion the leader 
sequence is removed. The insertion of a restriction site between the V(D)J- and the 
C-region in both vectors substituted original bases without changing the number of 
bases or affecting antigen binding and effector function of the antibodies.  
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Antibody Heavy chain sequence of variable region 
aCII >aCII-HC 
ACCGGTGTACATTCCcaggtgcaactgcagcagtcaggcgctgaactggcaaaacctggg 
acctcagtgaagatgtcctgcaaggcttctggctacacccttattagttactggatgaac 
tgggtaaaacagaggcctggacagggtctggaatggattggggctattaatcctagcaat 
ggttatactgagtacaatcagaagttcaaggacaaggccatattgactgcagacaaatcc 
tccagcacagcctacatgcaactgagcagcctgacatctgaggactctgcagtctattac 
tgtgcaagagaggactacggtagtacccactttgactactggggccaaggcaccactctc 
acagtctcctcaGCGTCGAC 
 
M2139 >M2139-HC 
ACCGGTGTACATTCCcaggtccagctgcagcagtctggggctgaactggcaagacctggg 
acctcagtgaagatgtcctgcaaggcttctggctacgcctttattagctactggatgaac 
tgggtaaaacagaggcctggacagggtctggaatggattggggctattaatcctagcgat 
ggttatactgagtacaatcaaaagttcaaggacaaggccataatgactgcagacagatcc 
tccagcacagcctacatgcaactgagcagccttacatctgaggactctgcactctattac 
tgtgcaagatatggtggatactttgactactggggccaaggcaccactctcacagtctcc 
tcaGCGTCGAC 
 
ACC1 >ACC1-HC 
ACCGGTGTACATTCCgaagtgaagcttgaggagtctggaggaggcttggtacaacctgga 
ggatccatgaaactctcttgtgctgcctctggattcacttttagtgacgcctggatggac 
tgggtccgccagtctccagagaaggggcttgagtgggttgctgaaattagaaacaaagtt 
aataatcatgcaacaaactatgctgagtctgtgaaagggaggttcaccatctcaagagat 
gattccagaagtgttgtctacctgcaaatgaacaacttaaaacctgaagacactggcatt 
tattattgtaccgggctaacgtttgactattggggccaaggcaccactctcacagtctcc 
tcaGCGTCGAC 
 
GG-
CIIC1 
>GG-CIIC1-HC 
ACCGGTGTACATTCCcaggtccaactgcagcagcctggggctgacctggtgaggcctggg 
gtttcagtgaagctgtcctgcaaggcttctggctacaccttcaccagctactggatgaac 
tgggtgaagcagaggcctggacaaggccttgagtggattggcatgattcatccttccgat 
agtgaaactaggttaagtcagaagttcaaggacaaggccacattgactgtagacaaatcc 
tccagcacagcctacatgcagctcagcagcccgacatctgaggactctgcggtctattac 
tgtgcaagattgaaacccgggggcacctggtttgcttactggggccaagggactctggtc 
actgtctctgcaGCGTCGAC 
 
E-CIIC1 >E-CIIC1-HC 
ACCGGTGTACATTCCcaggtccaactgcagcagcctggggctgacctggtgaggcctggg 
gtttcagtgaagctgtcctgcaaggcttctggctacaccttcaccagctactggatgaac 
tgggtgaagcagaggcctggacaaggccttgagtggattggcatgattcatccttccgat 
agtgaaactaggttaagtcagaagttcaaggacaaggccacattgactgtagacaaatcc 
tccagcacagcctacatgcagctcagcagcccgacatctgaggactctgcggtctattac 
tgtgcaagattgaaacccgagacctggtttgcttactggggccaagggactctggtcact 
gtctctgcaGCGTCGAC 
 
Table 5 Heavy chain VDJ region sequences. The sequences are denoted in the Fasta file 
format where every line harbours 60 nucleotides. Small letters indicate V(D)J region 
sequences. The leader sequence and the connection to the constant parts are depicted in 
large letters and are underlaid in yellow. Restriction sites for cloning are underlined (HC: 
AgeI, SalI). Bright orange sequences are V- or J-segments that have been added to 
complete the published VDJ region sequence (white background) according to the germ line 
sequences to obtain full-length genes. Corrections of the published V-region sequences back 
to the germ line sequence or corrections according to the amino acid sequence are shown 
intense orange. GG-CIIC1 HC and E-CIIC1 HC differ only in 2 but fundamentally different 
amino acids. Published nucleotide and amino acid sequences were controversial. Both HC 
go together with the CIIC1 LC. 
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Antibody Light chain sequence of variable region 
aCII >aCII-LC 
ACCGGTGTACATTCAgacatccagatgactcagtctccagcctccctatctgcatctgtg 
ggagaaactgtcaccatcacatgtcgagcaagtgagaatatttacagttatttagcatgg 
tatcagcagaaacagggaaaatctcctcagctcctggtctataatgcaaaaaccttagca 
gaaggtgtgccatcaaggttcagtggcagtggatcaggcacacagttttctctgaagatc 
aacagcctgcagcctgaagattttgggagttattactgtcaacatcattatggtactcct 
cggacgttcggtggagggaccaagctggaaatcaaaCGTACG 
 
M2139 >M2139-LC 
ACCGGTGTACATTCAgacattgtgctcacccaatctccagcttctttggctgtgtctcta 
gggcagagagccaccatctcctgcagagccagtgaaagtgttgaatattttggcacgagt 
ttaatgcagtggtaccaacagaaaccaggacagccacccaaactcctcatctatgctgca 
tccaacgtagaatctggggtccctgccaggtttagtggcagtgggtctgggacagacttc 
agcctcaacatccatcctgtggaggaggatgatattgcaatgtatttctgtcagcaaagt 
agggaggttccgtacacgttcggaggggggaccaagctggaaataaaaCGTACG 
 
ACC1 >ACC1-LC 
ACCGGTGTACATTCAgatattgtgctaactcagtctccagcttctttggctgtgtctcta 
gggcagagggccaccatctcctgcagagccagcgaaagtgttgataattatggcattagt 
tctatgaactggttccaacagaaagcaggacagccacccaaattcctcatctatgctgca 
tccaagcaaggatccggggtccctgccaggtttagtgggagtgggtctgggacagacttc 
agcctcatcatccatcctgtagaggaggatgacactgcagtgtatttctgtcagcaaagt 
aagggggttccgtacacgttcggaggggggaccaagctggaaataaaaCGTACG 
 
CIIC1 >CIIC1-LC 
ACCGGTGTACATTCAgacattgtgatgacccaatctccagcttctttgactgtgtctcta 
gggcagagggccaccatatcctgcagagccagtaaaagtgttgatagttatggcaatagt 
tttatggaatggtaccaacagaaaccaggacagccacccaaactcctcatctatcgtgca 
tccaacctagaatctgggatccctgccaggttcagtggcagtgggtctcggacagacttc 
accctcaccattaatcctgtggaggctgatgatgttgcaacctattactgtcaacaaagt 
aatgaggatccgtacacgttcggaggggggaccaagctggaaataaaaCGTACG 
 
Table 6 Corresponding light chain V-region sequences. Annotations are according to Table 
5. Restriction sites for cloning are underlined (LC: AgeI, BsiWI). Flanking germ line 
sequences that have been added to the published sequence (white background) are shown 
in bright green. Corrections of the published V-region sequences are shown intense green. 
The CIIC1 LC goes with either the GG-CIIC1 HC and the E-CIIC1 HC. 
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Antibody IgG1 heavy chain full length sequence of C57/B6 mouse strain 
aCII >aCII-IgG1 
ATGGGATGGTCATGTATCATCCTTTTTCTAGTAGCAACTGCAACCGGTGTACATTCCcag 
gtgcaactgcagcagtcaggcgctgaactggcaaaacctgggacctcagtgaagatgtcc 
tgcaaggcttctggctacacccttattagttactggatgaactgggtaaaacagaggcct 
ggacagggtctggaatggattggggctattaatcctagcaatggttatactgagtacaat 
cagaagttcaaggacaaggccatattgactgcagacaaatcctccagcacagcctacatg 
caactgagcagcctgacatctgaggactctgcagtctattactgtgcaagagaggactac 
ggtagtacccactttgactactggggccaaggcaccactctcacagtctcctcaGCGTCG 
ACGACACCCCCATCTGTCTATCCACTGGCCCCTGGATCTGCTGCCCAAACTAACTCCATG 
GTGACCCTGGGATGCCTGGTCAAGGGCTATTTCCCTGAGCCAGTGACAGTGACCTGGAAC 
TCTGGATCCCTGTCCAGCGGTGTGCACACCTTCCCAGCTGTCCTGCAGTCTGACCTCTAC 
ACTCTGAGCAGCTCAGTGACTGTCCCCTCCAGCACCTGGCCCAGCCAGACCGTCACCTGC 
AACGTTGCCCACCCGGCCAGCAGCACCAAGGTGGACAAGAAAATTGTGCCCAGGGATTGT 
GGTTGTAAGCCTTGCATATGTACAGTCCCAGAAGTATCATCTGTCTTCATCTTCCCCCCA 
AAGCCCAAGGATGTGCTCACCATTACTCTGACTCCTAAGGTCACGTGTGTTGTGGTAGAC 
ATCAGCAAGGATGATCCCGAGGTCCAGTTCAGCTGGTTTGTAGATGATGTGGAGGTGCAC 
ACAGCTCAGACGAAACCCCGGGAGGAGCAGATCAACAGCACTTTCCGTTCAGTCAGTGAA 
CTTCCCATCATGCACCAGGACTGGCTCAATGGCAAGGAGTTCAAATGCAGGGTCAACAGT 
GCAGCTTTCCCTGCCCCCATCGAGAAAACCATCTCCAAAACCAAAGGCAGACCGAAGGCT 
CCACAGGTGTACACCATTCCACCTCCCAAGGAGCAGATGGCCAAGGATAAAGTCAGTCTG 
ACCTGCATGATAACAAACTTCTTCCCTGAAGACATTACTGTGGAGTGGCAGTGGAATGGG 
CAGCCAGCGGAGAACTACAAGAACACTCAGCCCATCATGGACACAGATGGCTCTTACTTC 
GTCTACAGCAAGCTCAATGTGCAGAAGAGCAACTGGGAGGCAGGAAATACTTTCACCTGC 
TCTGTGTTACATGAGGGCCTGCACAACCACCATACTGAGAAGAGCCTCTCCCACTCTCCT 
GGTAAATGACGCGTACG 
 
Table 7 Example of complete anti-CII IgG1-HC antibody gene. Annotations are according to 
Table 5. Start and stop codon are shown in red. Restriction sites for cloning are underlined 
(HC: AgeI, SalI, BsiWI). The V-region (small letters) was cloned between the AgeI 
(A^CCGGT) and the SalI (G^TCGAC) restriction sites into the vector backbone (large letters) 
containing part of the leader sequence and the IgG1-HC C-region described for the C57Bl/6 
mouse strain followed by the BsiWI (CGTACG) restriction site.  
 
Antibody kappa light chain full length sequence of C57/B6 mouse strain 
aCII >aCII-kappa 
ATGGGATGGTCATGTATCATCCTTTTTCTAGTAGCAACTGCAACCGGTGTACATTCAgac 
atccagatgactcagtctccagcctccctatctgcatctgtgggagaaactgtcaccatc 
acatgtcgagcaagtgagaatatttacagttatttagcatggtatcagcagaaacaggga 
aaatctcctcagctcctggtctataatgcaaaaaccttagcagaaggtgtgccatcaagg 
ttcagtggcagtggatcaggcacacagttttctctgaagatcaacagcctgcagcctgaa 
gattttgggagttattactgtcaacatcattatggtactcctcggacgttcggtggaggg 
accaagctggaaatcaaaCGTACGGATGCTGCACCAACTGTATCCATCTTCCCACCATCC 
AGTGAGCAGTTAACATCTGGAGGTGCCTCAGTCGTGTGCTTCTTGAACAACTTCTACCCC 
AAAGACATCAATGTCAAGTGGAAGATTGATGGCAGTGAACGACAAAATGGCGTCCTGAAC 
AGTTGGACTGATCAGGACAGCAAAGACAGCACCTACAGCATGAGCAGCACCCTCACGTTG 
ACCAAGGACGAGTATGAACGACATAACAGCTATACCTGTGAGGCCACTCACAAGACATCA 
ACTTCACCCATTGTCAAGAGCTTCAACAGGAATGAGTGTTGAAAGCTT 
 
Table 8 Example of corresponding anti-CII kappa-LC antibody gene. Annotations are 
according to Table 5. Start and stop codon are shown in red. Restriction sites for cloning are 
underlined (LC: AgeI, BsiWI, HindIII). The V-region (small letters) was cloned between the 
AgeI (A^CCGGT) and the BsiWI (C^GTACG) restriction sites into the kappa vector backbone 
(large letters) containing part of the leader sequence and the kappa-LC C-region described 
for the C57Bl/6 mouse strain followed by the HindIII (A^AGCTT) restriction site. 
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4.1.2. Plasmid Preparation 
V-region sequences of IgH (Table 5) and IgL (Table 6) were ordered at MrGene, 
then cloned and colonies were prepped and sequenced as described in 3.1.. If 
sequencing revealed perfect sequence match with ordered sequences in an 
alignment BLAST (http://blast.ncbi.nlm.nih.gov/Blast.cgi), the vectors were 
quantitatively propagated for cell culture transfection.  
 
 
 
4.2. Antibody Expression 
4.2.1. HEK293T Expression Machines 
Corresponding IgH and IgL vectors were co-transfected, and cells receiving at least 
one of both plasmids were capable of producing fully functional tetrameric antibodies 
containing 2 heavy and 2 light chains. Transfection efficiency was assessed by 
measuring the antibody concentration in the supernatant via concentration ELISA. 
Antibody dilution series of known concentrations revealed antibody concentration in 
the supernatant samples via inserting colorant intensity into the standard curve. 
Hereby expression was proofed for all antibodies, which confirmed functionality of our 
vector constructs.   
Additional co-transfection with a GFP expressing vector was used for optimizing 
transfection efficiency via directly analyzing plasmid containing cells under 
fluorescence microscopy.  
After sterile filtration to remove residual cell contamination, antibodies in the 
supernatant were retained and eluted in a protein G sepharose column (3.2.3.). Final 
protein yield after buffer exchange to PBS was determined on a NanoDrop® 
photospectrometer. The purification step yielded more than 90% of the initial amount 
of antibodies in the supernatant.  
 
Interestingly the different anti-CII antibodies showed markedly different expression 
yield (Table 9) though all antibody chains had identical constant region sequences 
and plasmid vector backbones. Obviously HEK293T cells, which are commonly used 
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as protein expression machineries, prefer the expression of certain amino acid 
sequences to others. V-region amino acid sequences may influence protein folding 
and interaction with ribosomes, ER, chaperones, modification enzymes and the 
secretion machinery. Cells transfected with aCII-1-5 and M2139 antibodies showed 
very high expression yield compared to transfection with other antibodies. 
Comparability was achieved by transfecting antibodies in parallel.  
 
IgG1 Antibody Expression [mg / plate] 
aCII 1-5  0,250 
M2139 0,700 
ACC1 0,100 
CIIC1-GG 0,050 
CIIC1-E 0,200 
Table 9 Expression efficiency of anti-CII antibodies in HEK293T cells. The amount of 
antibody yield per transfected plate of 70% confluent cells is the mean value of more than 
500 transfections where several batches of different antibodies were transfected in parallel.  
 
 
4.2.2. Antibody Quality 
To verify the quality of the purified antibodies a denaturizing reducing SDS-PAGE 
separated the subunits of every antibody.  
This expression quality control showed that all anti-CII antibodies were expressed in 
their correct tetrameric conformation consisting of 2 heavy and 2 light chains. The 
single IgH ran at about 50kDa – depending on the V-region sequence length – the 
IgL at about 25kDa. We therefore assumed that all antibody subunit chains must 
have been assembled to form a native antibody, because Protein G sepharose 
purification only retains fully folded IgG heavy chain dimers. Retention of light chains 
in the column could have only been possible, if they were attached to the heavy chain 
dimer to form the antibody tetramer.  
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Figure 9 SDS-PAGE analysis of anti-CII antibody conformation. Denaturisation and 
breakage of disulfide bonds separated the 2 heavy and 2 light chains from each other. This 
quality control shows that every subunit of the antibodies was expressed, and that antibodies 
were secreted after transfection in a tetrameric confirmation. sial  indicates antibodies after 
enzymatic galactosylation and sialylation. cc denotes cell culture purified antibodies before 
enzymatic glycosylation. Every gel was run with a protein standard containing peptides of 
known weight to conclude protein weight in the samples. Weight is indicated in Kilodalton 
(kDa) from 170kDa to 26kDa. One Dalton is the molecular weight of one hydrogen atom.  
 
 
4.2.3. Enzymatic Glycosylation of Antibodies 
To determine the Fc-glycan structure, oligosaccharides were cleaved by the bacterial 
enzyme EndoS, which specifically cleaves the N-linked Fc-oligosaccharide between 
the first and the second N-acetylglucosamine. EndoS is a defence enzyme secreted 
by Streptococcus pyogenes. Cleavage of the complete Fc-oligosaccharide abrogates 
IgG effector function, thus anti-bacterial antibodies lose their pathogen clearance 
properties.  13 
We used EndoS to cleave the Fc-glycans of the anti-CII antibodies for analyzing them 
in the mass spectroscopy.  
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Antibodies produced by HEK293T cells had short oligosaccharides lacking terminal 
sialic acid. About two thirds of the bisecting Fc-glycans were in the G0 glycoform 
terminating with N-acetylglucosamines.  
However, this short IgG Fc-glycans lacking terminal sialic acid and galactose were 
mainly associated with proinflammatory properties. To test the antiinflammatory 
potential of sialylated antibodies we had to enzymatically galactosylate the terminal 
N-acetylglucosamines with &-1,4-galactosyltransferase and further sialylate them with 
&-1,6-sialyltransferase. The more efficient terminal N-acetylglucosamines were 
galactosylated the more binding sites for sialic acids were available. After optimizing 
reaction conditions for the enzymatic glycosylation assay we were able to generate 
antibodies with Fc-glycans of which more than 50% harboured terminal sialic acid.  
Enzymatic glycosylation was first performed with the aCII-1-5 and the M2139 
antibody, which yielded highest expression amount in cell culture, whereby the 
M2139 antibody additionally had a higher Fc-glycosylation rate than the aCII 1-5 in 
the first glycosylation assay though both had identical Fc-region sequences. The 
M2139 additionally had the highest expression rate in cell culture. We used those two 
antibodies for treating arthritic mice in a first therapeutic trial. 
In the second enzymatic glycosylation reaction all antibodies (aCII 1-5, M2139 and 
ACC1) had more than 50% sialylated isotypes. All 3 antibodies were used in the 
second treatment.  
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Figure 10 Fc-glycan structure of antibodies produced in cell culture (cc) and after enzymatic 
glycosylation (sial). Antibodies produced by HEK293A cells predominantly have short Fc-
glycans with terminal N-acetylglucosamine. To test for the antiinflammatory potential of 
sialylated IgG antibodies, enzymatic attachment of galactose and sialic acid was required.  
 
 
Antibody total G0 % total G1/2 % total S1/2 % Treatment 
aCII 1-5 cc 67,85% 32,15% 0,00% 
M2139 cc 60,94% 39,07% 0,00% 
Ctrl 
aCII 1-5 sial 40,50% 43,97% 15,54% 
M2139 sial 15,65% 65,89% 18,46% 
1.Trial 
aCII 1-5 sial 5,75% 43,24% 51,00% 
M2139 sial 5,28% 43,38% 51,33% 
ACC1 sial 6,82% 41,77% 51,41% 
2.Trial 
Table 10 IgG1 Fc-glycosylation pattern. Anti-CII antibodies aCII-1-5 and M2139, which had a 
high expression yield in cell culture (cc), were enzymatically glycosylated (sial). This table 
shows glycosylation patterns indicating the percentage of Fc-glycan isoforms of different 
monoclonal antibodies. Fc-oligosaccharides contain terminal N-acetylglucosamine (G0), one 
or two terminal galactoses (G1/2) and one or two terminal sialic acids (S1/2). For the 
treatment of arthritic mice we used cell culture antibodies as a control. For the first treatment 
of arthritic mice (1.Trial) we used antibodies of which more than 15% of the Fc-glycans were 
sialylated. After optimizing glycosylation conditions we could treat arthritic mice (2.Trial) with 
anti-CII antibodies of which more than 50% contained sialylated Fc-glycans. Less than 7% 
were in the proinflammatory G0 isoform.  
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Figure 11 IgG1 Fc-glycosylation pattern. This graph depicts the relative amount of Fc-glycan 
isoforms of the different monoclonal anti-CII antibodies before (cc) and after enzymatic 
glycosylation (sial) shown in Table 10. After further optimizing enzymatic reaction conditions, 
we could treat arthritic mice (2.Trial) with antibodies, where more than 90% of Fc-glycans 
were terminally galactosylated (G1/2) or sialylated (S1/2).   
 
 
4.2.4. Reactivity Properties of Anti-Collagen II Antibodies 
Though some reactivity properties of the anti-CII antibodies have been described 35, 36, 
we verified collagen binding of the anti-CII IgG1 constructs to collagen type II of 
different species (3.2.7.). Trimeric CII proteins consisting of three identical "-collagen 
subunit chains non-covalently wrapped around each other to form a triple helix 
assembled into long fibrils and fibers that contribute to the viscosity of the synovial 
fluid in limb joints of mammals. CII is a conserved protein throughout mammalian 
species with a repeating core amino acid motif having a Glycin on every third 
position. Several immunodominant epitopes on CII have been shown to exist 
exclusively for B-cells or T-cells. Nevertheless CII proteins differ among species, 
leading to unique species specific epitopes for whether B- or T-cells.  35, 42, 43 
CII of mouse, chicken, human and bovine origin was coated on ELISA plates. All 
antibodies were tested for their reactivity against all CII species and characterized on 
an affinity plot (Figure 12). The better binding of one antibody to one CII was, the 
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lower was the antibody concentration to keep the antibody bound to CII during 
washing. Binding affinity was characterized by the optical density (OD). The more 
antibodies were bound to CII, the more HRP-coupled antibodies could bind to the 
anti-CII antibodies and the more colorant could be developed, which was then 
measured photometrically. As a negative control we used an IgG1 antibody, 
produced via the same expression vector cloning approach as the anti-CII antibodies, 
binding TNP-modified proteins – a modification motif that is not present in any CII.  
 
The M2139 antibody showed highest expression yield in cell culture and was the best 
to be glycosylated in the first glycosylation assay. Now it showed highest binding 
affinity to CII of mouse, chicken and bovine origin compared to other anti-CII 
antibodies.  
Interestingly, the aCII-1-5 antibody showed highest binding affinity to human CII 
probably due to the immunization protocol using human CII to generate this antibody, 
but binding to chicken and bovine CII was completely abrogated, indicating that the 
aCII-1-5 bound a different CII epitope than M2139. Importantly the aCII-1-5 bound 
mCII with high affinity too. Therefore, additionally to their properties of high 
expression yield, aCII and M2139 were chosen first for the treatment of arthritic mice.  
The ACC1 was described to bind denatured and citrullinated CII. During inflammation 
of joints, necrotic cells release intracellular peptidyl arginine deaminase (PAD1), 
which leads to citrullination of extracellular CII in the inflammed tissue. Citrullination 
disables CII to form proper Collagen helices and fibrils and therefore results in the 
denaturation of CII and the progression of an arthritic phenotype. 36 ACC1 showed 
binding to all CII species. High binding of ACC1 was achieved by denaturation of 
mouse CII by heating it for 10 minutes at 94°C. Denaturation of native CII helices and 
fibrils disrupted binding properties of all other antibodies (Data not shown). To 
attenuate the progression of severe arthritis we included ACC1 in the treatment 
cocktail (aCII-1-5, M2139) for the second trial.  
GG-CIIC1 and E-CIIC1 antibodies showed worse expression yield, had lower binding 
affinities to human and mouse CII than other anti-CII antibodies (aCII-1-5, M2139, 
ACC1) and showed no binding against chicken and bovine CII. E-CIIC1 all together 
showed similar binding properties to aCII-1-5, but at lower affinity. To reduce the 
54 4. Results 
 
amount of antibodies with poor binding affinities, we excluded GG-CIIC1 and E-CIIC1 
from the treatment cocktail. 
 
To verify that enzymatic Fc-glycosylation of the antibodies purified from the cell 
culture did not influence their antigen binding affinities, we compared binding 
properties of the antibodies before and after enzymatic glycosylation (Figure 13). 
ELISA testing was performed analogue to Figure 12. Binding affinities of different Fc-
glycan isoforms of aCII-1-5, M2139 and ACC1 to mouse, chicken, human and bovine 
CII revealed no binding propertiy differences. aCII-1-5 and M2139 produced in cell 
culture had short Fc-glycan isoforms (G0). They showed similar binding properties 
after enzymatic Fc-glycosylation. Fc-sialylation of 18 or 50% did not influence 
collagen binding. ACC1 before sialylation did not bind any collagen, probably due to 
incorrect sample handling. Anyway, ACC1 was included in the second treatment 
cocktail.  
Results in Figure 13 were consistent with results of Figure 12 and proofed binding of 
our anti-CII antibody constructs to different CII species and thus qualified them for 
testing our hypothesis of treating arthritic mice with anti-CII binding antibodies 
harbouring anti-inflammatory properties.   
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Figure 12 Reactivity Pattern of anti-CII antibodies against different CII species. Binding 
affinities of anti-CII IgG1 antibodies to mouse (mCII), chicken (chCII) human (hCII) and 
bovine (bCII) CII are shown. Optical density at 450nm (OD450) was measured at different 
anti-CII antibody concentrations (Ab conc.). aCII refers to the aCII-1-5 antibody.  
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Figure 13 Reactivity Pattern of different Fc-glycan isoforms of anti-CII antibodies (aCII-1-5, 
M2139, ACC1). Fc-glycosylation pattern did not influence binding affinities of antibodies to 
CII species. IgG1 harvested from the cell culture (NoSial) showed same binding properties to 
CII species than after enzymatic glycosylation. Fc-sialylation (50%Sial or 18%Sial) did not 
change Fab binding properties. Binding affinities of anti-CII antibodies to mouse (mCII), 
chicken (chCII) human (hCII) and bovine (bCII) CII are indicated by optical density at 450nm 
(OD450) at different anti-CII antibody concentrations (Ab conc.).  
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4.3. Treatment of Arthritic Mice with Sialylated 
Antibodies 
 
4.3.1. The Collagen Induced Arthritis Mouse Model 
Collagen-induced arthritis (CIA) in mice is an important disease model of human 
rheumatoid arthritis (RA), which is characterized by autoreactive B- and T-cells 
against synovial tissue components like collagen type II (CII). 44 Autoantibodies 
produced by Plasma B-cells are active through Fc-receptors on immune cells like 
macrophages and by activation of the complement system via binding of C1q. 
Susceptibility to CIA and RA is associated with the expression of certain MHC 
haplotypes 39, whereby tolerance in non-susceptible mouse strains can be broken by 
increasing the amount of avirulent inactivated Mycobacterium tuberculosis (H37Ra) in 
complete Freund!s adjuvants (CFA). It has been reported that H37Ra in high doses is 
necessary to provide enough stimulation of Toll-like receptor 2 (TLR2) 45 on dentritic 
cells (DC) to induce the expression of proinflammatory cytokines and to trigger 
immune response even in H-2b harbouring “non-susceptible” mouse strains.  40 
 
However, problems inducing CIA in H-2b mice like C57BL/6 have been described, 
and several protocols have been published in recent years dealing with this 
difficulties. Immunization time-points, booster injections, the use of CFA with different 
amounts of H37Ra, the use of heterologues CII species and even the contribution of 
the mouse facility have been topic of discussions.  39, 40, 41 
After studying literature and with great advice from Andrei Kruglov from the Sergei 
Nedospasov group at the DRFZ, we decided to immunize C57BL/6 mice with chCII in 
CFA containing 5mg/ml inactivated H37Ra. Heterologues chCII is necessary to 
overcome tolerance against self-CII as it would be the case with the more 
homologues bCII. A second booster immunization at day 21 again with chCII in CFA 
(5mg/ml H37Ra) was necessary for the development of the arthritic phenotype.  
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However, about 20% of the mice developed ulcerations at sites of injection and had 
to be sacrificed. Our CIA protocol led to disease onset in C57BL/6 mice within one 
week after booster immunization. Peak incidence and severity were achieved around 
day 42 after the first immunization. About 50% of the C57BL/6 mice receiving the CIA 
protocol developed arthritis. The mean clinical value, which is a mean value 
measuring the severity of all arthritic limbs in a group (3.3.4., Figure 8), reached a 
peak of between 3 and 4. Read out of the experiments was set at day 42 after the 
first immunization, because limbs with sustained severe ankylosis cripple. During that 
process swelling goes down and mean clinical score read out is no representative 
value for severity any more. After setting the protocol for C57BL/6 mice, a CIA 
protocol for Fc!RIIB-/- mice was established. Fc!RIIB-/- mice have a C57BL/6 
background only lacking the inhibitory Fc!RIIB-/- receptor on immune cells, which 
makes them more susceptible to CIA though carrying the H-2b haplotype.  30  
It has been suggested that sialylated antibodies have antiinflammatory potential due 
to their altered affinity to Fc!-receptors. Affinity of IgG antibodies to their Fc!-
receptors triggering proinflammatory cascades is lowered according to Fc-sialylation, 
thus leading to less inflammatory effector potential. 20 Nourished by the identification 
of a lectin receptor called SIGN-R1 on macrophages, that binds sialylated IgG 
antibodies and contributes to their antiinflammatory effects, 22 and the Fc!RIIB-
independent inhibition of antigen presentation and T-cell activation,  28 we suggested 
a novel hypothesis of an Fc!RIIB-independent mechanism as the base of the anti-
inflammatory activity of sialylated IgG antibodies.  
We used Fc!RIIB-/- mice for treating arthritic mice with highly sialylated anti-CII IgG 
antibodies to additionally look for an Fc!RIIB-independent IgG effector mechanism. 
We applied the same immunization protocol for Fc!RIIB-/- mice as for the C57BL/6 
except of boosting them on day 14 with incomplete Freund!s adjuvants (IFA) not 
containing any inflammation stimulating H37Ra Mycobacteria tuberculosis. Up to 
90% of Fc!RIIB-/- mice developed arthritis on at least on limb with a peak mean 
clinical score of up to 6 (healthy and sick mice in one group together). Immunizing the 
mice first with chCII in standard CFA (1mg/ml H37Ra) even Fc!RIIB-/- mice showed 
the robust H-2b phenotype with only 30% of mice developing arthritis. No Fc!RIIB-/- 
mice showed any ulcerations or wounds at the site of injection at all.  
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Figure 14 Arthritis severity and arthritis incidence in C57BL/6 and Fc!RIIB-/- mice. 
Establishment of CIA in C57BL/6 and Fc!RIIB-/- mice was set using different immunization 
protocols. The mean clinical score is a value of arthritis severity of all healthy and sick mice 
of one group, including all 4 limbs of every mouse (Figure 8). The arthritis incidence is a 
measure of the relative amount of arthritic mice in one group. A mouse is scored arthritic if it 
has at least one limb scored not healthy (>0). 
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4.3.2. Treatment Scheme 
The induction of CIA leads to an immune response against chCII. Cross-reacting B- 
and T-cells trigger inflammation in host joint collagen. A self-propagating process in 
the inflamed joints starts and an arthritic phenotype is established. Because of the 
host immune reaction against self-CII, we antigen-specifically target mCII with 
sialylated anti-mCII antibodies to test for their anti-inflammatory activity. We used two 
protocols in this experiment to test for the influence of injection time-points, the 
amount of antibody and sialylation degree necessary to show effects. Sialylated 
antibodies were injected before immunization and at different time points before the 
boost to inhibit the development of an immune reaction against self-CII. To observe 
effects of intraperitoneal (i.p.) and intravenous (i.v.) administration, antibodies were 
injected i.p. in the first and i.v. in the second trial.  
In the 1.Trial we injected twice 100µg of an antibody cocktail containing 50µg aCII 1-5 
and 50µg M2139 – 15-18% of which had terminal sialic acid – in Fc!RIIB-/- mice 
(n=10). An IFA boost was given at day 21. In the 2.Trial of this experiment Fc!RIIB-/- 
mice (n=10) were injected twice 450µg of an antibody cocktail containing 150µg aCII 
1-5, 150µg M2139 and 150µg ACC1. All antibodies in this cocktail had more than 
50% terminal sialic acid.  
One control group in each trial received corresponding amounts of the same but 
unsialylated antibody cocktail. Control antibodies were purified from cell culture 
supernatant and did not receive the enzymatic Fc-glycosylation protocol.  
The second control group in each trial received a corresponding volume of PBS 
without antibodies.  
 
 4. Results 61 
 
 
Figure 15 Treatment scheme. In the 1.Trial (I.) Fc!RIIB-/- mice (n=10) received a total of 
200µg of up to 18% sialylated antibodies (aCII 1-5, M2139) with two injections 
intraperitoneally. One day before and nine days after the first immunization 100µg of antibody 
cocktail were injected. For the 2.Trial (II.) Fc!RIIB-/- mice (n=10) received a total of 900µg 
(150µg of aCII, M2139 and ACC1 each) via two injections of 450µg intravenously one day 
before immunization and one day before booster injection. 
 
 
4.3.3. Sialylated Antibodies Attenuate Disease Progression 
Fc!RIIB-/- mice were treated with sialylated anti-CII IgG1!s according to the treatment 
scheme in Figure 15. In the 1.Trial mice received less amount of antibody, which 
were also less sialylated; in the 2.Trial mice received a higher dose of highly 
sialylated antibodies. In both trials one of the control groups received corresponding 
amounts of non-sialylated antibodies. Second control group received PBS. Mice were 
observed thrice a week blinded for the development of arthritis.  
 
Interestingly disease onset was not altered by the injection of the antibodies and 
started within one week after booster injection with IFA in all groups independent of 
the amount of administered antibodies. The second booster injection triggered 
disease onset in all groups, but mice receiving non-sialylated control antibodies 
developed severe arthritis immediately within one week. Compared to the PBS group 
the non-sialylated antibodies had a severity promoting effect in the early phase of 
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disease. As suggested by Parekh et al  16, 34 in the 1980!s and reviewed in 2009  12 
antibodies in rheumatoid arthritis were associated with short Fc-oligosaccharides 
predominantly ending with terminal N-acetylglucosamine. However, in the 2.Trial high 
amounts of control antibodies did not promote severity in the late phase of disease.  
Around day 28 PBS control mice started developing severe arthritis as seen in the 
establishment protocol.  
In both trials mice given sialylated IgG antibodies behaved similar to PBS control 
mice during the first week of disease onset, but were prevented from developing 
severe arthritis until evaluation day 42. Even those animals receiving only 200µg of 
less sialylated (<18%) antibodies were prevented from developing severe arthritis. 
These results suggest that antibodies of which about 15% are terminally sialylated 
are sufficient even at lower dose to protect joints from severe arthritic inflammations. 
The results of both trials leave the question open if time-points of injection and 
boosting are more important than the amount of antibodies to be injected.  
 
Incidence rates of mice receiving sialylated anti-CII antibodies were between 60% 
(1.Trial) and 70% (2.Trial) at day 42, which were 20-40% less than in both control 
groups. Non-sialylated IgG!s with shorter Fc-glycans increased incidence rates at the 
beginning of the disease to be 20-40% higher around day 28, but incidence curves 
adjusted to those from the PBS group in the later phase of disease.  
 
We observed that sialylated antibodies inhibited the development of severe arthritis 
and reduced incidence rates. However, sialylated antibodies did not prevent from 
disease onset. Even highly sialylated antibodies at high doses do not alter severity or 
incidence curves compared to lower doses of less sialylated IgG!s. A sufficient 
amount of sialylated antibodies seems to be necessary to switch off part of the 
immune response.  
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Figure 16 Severity and incidence of arthritis after treatment with sialylated antibodies. In both 
trials one group of mice (n=10) received a sialylated IgG1 antibody cocktail (IgG1 sial), one 
group (n=10) receive the corresponding non-sialylated IgG1 cocktail (IgG1 ctrl) and the last 
group (n=10) was the PBS control group (PBS). In the 1.Trial 200µg IgG1 sial (<18% 
sialylated) were administered. In the 2.Trial 900µg IgG1 sial (>50% sialylated) were given. 
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4.3.4. Sialylation Pattern of Serum IgG 
As observed during establishment of the CIA protocol, not all of the mice developed 
arthritis. Depending on the immunization protocol a fraction stayed healthy.   
To examine differences in the glycosylation pattern of anti-CII antibodies in mice that 
stayed healthy despite applying the CIA protocol and in mice that became sick after 
CIA immunization, we pooled equal volumes of sera from healthy mice and from sick 
mice out of untreated control groups, respectively. None of the mice had received any 
antibodies. 100µl serum of 5 healthy mice were pooled and incubated with chCII 
immobilized in an agarose bead column and fractions containing antibodies that had 
been retained in the column were pooled and used for MALDI-TOF analysis of their 
Fc-glycan pattern together with the whole serum IgG containing flow through that did 
not bind to the chCII column. To search for difference in the Fc-glycan pattern 
between healthy and arthritic mice, the same procedure was applied with serum IgGs 
of 5 severely arthritic mice (clinical score per mouse %10). 
Results of Fc-glycan analysis of serum anti-CII and flow through IgG-glycosylation 
patterns claimed reduced Fc-sialylation of anti-CII IgGs as well as of flow through 
serum IgGs of severely arthritic mice compared to IgGs of their healthy littermates.  
Anti-chCII IgG!s of arthritic mice that might influence arthritic phenotype via cross 
reacting with self-mCII were retained in the chCII column. Alterations in the Fc-
glycosylation pattern could be observed (Figure 17). Arthritic mice displayed more 
anti-chCII IgG Fc-glycans  appearing in the G0 isoform (data not shown) compared 
with Fc-glycans of healthy mice. These results are consistent with previous findings 16, 
20, 33 that desialylated IgGs promote arthritic inflammations, whereas sialylated IgGs 
prevent from the development of arthritis. Additionally, the results of the two trials 
(4.3.3.), where arthritic mice were treated with sialylated and desialylated IgGs, have 
also led to the conclusion that sialylated IgGs can prevent from severe arthritis while 
desialylated IgGs promote inflammation. 
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Figure 17 Fc-sialylation of serum IgG!s of healthy and severely arthritic mice. Pooled serum 
IgG!s that were retained in a chCII column and corresponding flow through (FT) IgG!s of 
healthy mice and severely arthritic mice (clinical score per mouse %10) were analysed 
according to their Fc-sialylation pattern. Anti-CII IgG!s as well as other serum IgG!s of arthritic 
mice showed reduced Fc-sialylation.  
 
 
4.3.5. Serum Levels of Ig subclasses in arthritic and non-arthritic mice 
Another subject of our interest was whether Ig subclass (IgA, IgM and IgG) and IgG 
isotype (IgG1, IgG2a, IgG2b and IgG3) serum levels markedly differ between chicken 
CIA mice that had received sialylated or desialylated anti-CII antibodies or PBS. 
Additionally we wanted to examine, if the development of an arthritic phenotype 
correlates with the expression of certain Ig subclasses and isotypes.  
To analyse differences in serum Ig levels of mice from different groups of the 1.Trial 
and the 2.Trial, serum-ELISA (3.2.7.) was the method of choice. Antibodies in the 
sera of mice were tested on mCII and chCII. Bound antibodies were detected by 
HRP-coupled secondary antibodies directed against different mouse Ig subclasses 
and IgG isotypes. Photometric signals display the amount of anti-mCII and anti-chCII 
antibodies of different subclasses and isotypes in the serum.  
We supposed mCII to be the phenotype-causing antigen. Interestingly immune 
responses against mCII did not necessarily correlate with the immune response 
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against chCII. All ELISA data depicted in Figures 18-20 are taken from the 
2.Treatment-Trial (4.3.3.) and are representative for all experiments. Evaluation of 
the serum Ig content was done at day 42 (d42) after the 1.immunization with chCII. At 
this time-point no elevated IgG1-level was detectable that was due to the injection of 
sialylated or de-sialylated anti-CII IgG1 on d-1 and d13.  
 
First we examined the influence of sialylated anti-CII IgG1 antibodies that had been 
injected between d-1 and d13 on the expression of intrinsic anti-mCII and anti-chCII 
antibodies (IgG, IgG1, IgG2b, IgG2c, IgG3, IgM and IgA) at d42. Mice receiving 
sialylated anti-CII IgG1 had lower total serum IgG against mCII and chCII than the 
PBS control group and the group treated with de-sialylated IgG1 (anti-CII-cc) (Figure 
18). This result is consistent with the idea of a general immunosuppressive effect of 
sialylated antibodies. How sialylated anti-CII IgG1 antibodies suppress the general 
production of new IgGs remains to be elucidated. At d42 IgM levels of mice receiving 
sialylated antibodies were elevated, though these date were not reproducible. 
However, no significant differences in the expression of different intrinsic Ig 
subclasses could be observed. 
Additionally we investigated serum Ig levels of healthy and arthritic mice. To 
examine, if there was a general humoral mechanism controlling the development of 
arthritis, we analyzed healthy mice of all 3 groups, as well as arthritic mice of all 3 
groups. Arthritic mice had significantly higher levels of IgG2b and IgG2c (=IgG2a of 
C57BL/6) in blood serum compared to healthy mice at d42 supporting findings that 
these IgG subclasses have pathogenic properties in autoimmune disease.  10 Even 
though, mice receiving the CIA immunization protocol without displaying an arthritic 
phenotype had increased serum anti-mCII and anti-chCII antibody titers of different 
subclasses at the end of the experiment (day 42) at comparable levels to arthritic 
littermates, suggesting another mechanism critically regulating the switch between 
inflammation and tolerance (Figure 19). Sustained inflammation might therefore be 
due to high IgG2b and 2c levels.  
Indications that glycosylation pattern of IgG antibodies have a major impact on the 
development of arthritis had come from experiment 4.3.5., where arthritic mice had 
anti-chCII antibodies with less terminal sialic acid.  
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Take together, the results of Ig subclass serum ELISA supported the hypothesis of a 
major mechanism in autoimmune arthritis concerning the Fc-sialylation of IgG 
antibodies that contributed to an arthritic phenotype.  
One prognostically relevant observation has been made by looking at IgM levels at 
d12 (Figure 20) before the onset of arthritis between d15 and d25. Mice receiving 
sialylated IgG1 antibodies produced significantly higher amounts of anti-mCII IgM 
before the onset of the disease compared to desialylated anti-CII IgG1 and PBS 
control groups, but no differences could be observed concerning anti-chCII IgM. High 
anti-mCII IgM titers in blood serum before the onset of the disease seem to prevent 
from the development of arthritis. These results indicate a tightly regulated immune 
response against self-antigens. The initial phase of the immune response possibly 
predicts later clinical outcome. If sialylated anti-CII IgG1 antibodies directly trigger the 
early expression of IgM remains to be elucidated.  
The contribution of specific immunogenic CII epitopes as well as the role of regulatory 
(Treg) and proinflammatory (Th17) T-cells must as well be addressed for further 
understanding the mechanistical network that leads to the development of 
autoimmune CIA. Insights from disease mouse models can be an important guide for 
the translation of therapeutic approaches to human autoimmune diseases like 
rheumatoid arthritis. 
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Figure 18 Serum Ig levels at day 42 of CIA Fc!RIIB-/- mice treated with sialylated (anti-CII-
sial) or desialylated (anti-CII-cc) IgG1 antibodies. The control group received PBS. Intrinsic 
serum antibodies of every mouse were tested for reactivity against mouse CII (mCII) and 
chicken CII (chCII). Serum Ig subclasses were detected with secondary HRP-coupled 
antibodies specific for different subclasses. No significant differences in Ig subclass and IgG 
isotype distribution could be detected that were representative for other experiments, except 
that general IgG levels (all isotypes) were reduced in mice that received sialylated anti-CII 
IgG1 compared to those mice that did not receive antibodies.  
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Figure 19 Serum Ig levels of healthy and arthritic mice. Serum of all healthy and arthritic 
Fc!RIIB-/- mice from all groups (treated with anti-CII-sial, anti-CII-cc or PBS) of the 2.Trial 
(representative for all experiments) were taken together and tested for reactivity against mCII 
and chCII. Primary antibodies in the serum were detected by secondary HRP-coupled 
antibodies against different Ig subclasses. Reactivity to mCII was considered as phenotype 
relevant.  Proinflammatory IgG2b and IgG2c remained upregulated in arthritic mice. No other 
significant differences could be observed at day 42 (d42) after immunization.   
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Figure 20 IgM and IgG2b serum levels over time and in detail at day 12 after immunization 
(d12). IgM is significantly upregulated at d12 in mice that have received sialylated antibodies 
(anti-CII-sial) compared to mice that have received desialylated antibodies (anti-CII-cc) or 
control mice (PBS). Additionally IgM is upregulated at d12 in mice that stay healthy until the 
end of the experiment (d42). To compare, no significant differences in proinflammatory IgG2b 
expression at day were found in any of the groups over different time points.
 
  
5. Discussion 
This diploma project aimed to investigate the effect of sialylated IgG antibodies in a 
preclinical autoimmune disease mouse model.  Sialic acid is a sugar, which can be 
attached terminally to the IgG Fc-glycan.  Sialylated IgGs have been described to 
have novel effector functions. 7, 19, 20 Upon sialylation of the Fc-glycan, IgG antibodies 
switch from an activating to an inhibitory effector molecule. This effect of IVIG (serum 
IgG pool) was shown to be systemically translated by splenic marginal zone 
macrophages in mice. Due to several findings (unpublished) in our lab, there was 
strong indication that one could transfer this antiinflammatory property of sialylated 
IgG Fc!s by targeting the autoimmune disease causing self-antigen with sialylated 
IgGs that have antigen-specific Fab regions.  
Collagen-induced arthritis (CIA) is an autoimmune disease mouse model where 
collagen type II (CII) is the defined arthritic phenotype causing self-antigen. IgG 
antibodies produced by plasma cells act in concert with T-cells to promote arthritis.  
 
 
5.1. Newly Designed Antibodies Bind To Antigen  
To use the anti-inflammatory potential of IgGs for the treatment of CIA we designed 
highly sialylated anti-CII IgG1 antibodies to attenuate the host immune response 
against its self-CII in the synovial fluid. The V-region sequences of the antibodies 
were published. 34, 35, 36 A cocktail of these antibodies was known to efficiently induce 
arthritis at concentrations of about 9mg/mouse. 34, 43 Most of the antibodies were 
originally isolated from inflammatory IgG2a and IgG2b isotype expressing hybridoma 
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cells. 10, 35, 36 To be able to produce these antibodies separately and on different IgG 
subclasses like the less activating mouse IgG1 subclass 9 we cloned the antibodies. 
No data about the glycosylation status of these antibodies when trying out the 
arthritis induction experiments were found, suggesting that IgGs were in a less 
sialylated form to efficiently induce arthritis.  
Investigations on the degree of sialylation of our antibodies revealed that IgG1!s 
produced in cell culture did not contain any sialylated Fc-glycans. Fc-glycan patterns 
of these cell culture antibodies were associated with proinflammatory effector 
properties 12, 16, 18, 33 due to more than 2/3 of the Fc-glycans being in the G0 glycoform.  
IgG antibodies of healthy individuals show a sialylation degree of about 15%. Healthy 
mice examined in our study had about 20% sialylated IgGs. There exist no data if IgG 
subclasses are differently sialylated – neither in humans nor in mice. Therefore we 
suggested a sialylation degree of more than 15% in an antigen-specific IgG1 sample 
to be sufficient to show effects at the site of inflammation. One experiment was 
carried out with 18% sialylated IgG1, the 2.Trial with more than 50% sialylated IgG1. 
 
 
5.2. Sialylated IgG!s Prevent From Severe Arthritis 
5.2.1. Antigen-Specific Prevention From Severe Autoimmune Disease 
The only antiinflammatory approved products based on IgGs are IVIG (intravenous 
immunoglobulin G) biologics. 7, 21, 23 It has been shown that the antiinflammatory 
activity of IVIG is based on a small fraction of sialylated IgGs. 19, 20, 21 However, IVIG 
has a systemic shut-down effect on the immune system, including risk to increased 
susceptibility to pathogens, transfer of inadvertent immune responses and side 
effects including headache and fatigue, due to very high dose administration of off-
target IgGs. The transfer of pooled donor samples can also lead to variations in the 
quality of different batches.  19, 21, 23  
We were able to show that mice receiving the CIA protocol could be prevented from 
developing severe autoimmune arthritis, which was evoked by immune response 
against self-CII, by the administration of low dose recombinant anti-CII specific 
sialylated IgG1 antibodies.  
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Consisting with the results of recent publications  11, 12, 33 we found a correlation of the 
effector function of monoclonal antigen-specific antibodies with their differently 
glycosylated Fc portions. As suggested in the analysis of IgG Fc-glycans of patients 
with rheumatoid arthritis  12, 18, 33 and in our observations of CII-specific IgG Fc-glycans 
of arthritic and non-arthritic mice, vice versa the recombinant IgGs induce pro- and 
antiinflammatory activities upon application. Sialylated antibodies administered 
before and after induction of CIA inhibited the development of arthritis compared to 
the control group by exhibiting less than half of the clinical score. The clinical 
outcome was markedly beneficial, even though mice were not completely prevented 
from the induction of arthritis, suggesting additional molecular and cellular 
contributions to the origin of disease.  
The disease promoting effect of the desialylated anti-CII IgG1 hints to the binding of 
the antibodies to their joint targets. In vivo binding of the antibodies to CII in the 
synovium has been shown before. 6 
 
IVIG is administered at 2mg/g body weight, which 40,000µg per mouse per injection. 
We were able to achieve beneficial effects in arthritis therapy with up to 400-fold less 
amount of IgGs compared to IVIG by using sialylated antigen-specific IgG1 
antibodies, even suggesting a lower dose to achieve efficient effects, because 
elevated IgG1 levels in blood serum can be detected up to several weeks after 
injection. This suggests CII-specific antibodies to be present at saturated levels in the 
joint structures.  
Severe side effects of this therapy could not be observed by the experimenter. All 
mice in the different groups behaved according to their status of disease.  
 
5.2.2. Outlook 
It remains to be elucidated if administration of the sialylated autoantigen-specific IgGs 
after the establishment of the disease can attenuate arthritic symptoms. This 
question would be of particular medical relevance and would allow a more 
challenging comparison between approved medical therapeutics like IVIG and 
potential new recombinant biologics.   
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Another control necessary for preclinical studies would be the administration of an 
sialylated antigen-specific IgG1 antibody that binds no target in the mouse, to 
exclude off-target contributions, as well as anti-CII-specific antibodies that are 
completely abrogated in their Fc!-receptor signalling due to complete removal of their 
Fc-glycan by EndoS. 14 This could also point out differences in the proposed 
antiinflammatory signalling triggered by sialylated antibodies compared to a total 
abrogation of signalling due to the loss of the Fc-glycan. Concerning this, trials would 
proof that not only sialylated activation-failing IgGs in this model just simply block 
arthritogenic epitopes on CII to avoid binding of cytotoxic antibodies and activating T-
cells and therefore inhibiting the establishment of severe arthritic phenotypes; but 
that inhibitory signalling by sialylated antibodies is actively triggered. At least Fc-
sialylation decreases the binding of IgG1 to the activating Fc!-receptor III only by 
about 10-fold 20, but does not abrogate their interaction completely. Other interactions 
could though be blocked, because no activating IgG2a or 2b subclass can bind to CII 
to trigger activation and thus no Fc!-receptor IV signalling can take place.  
Further detailed investigations on the mode of actions of sialylated IgG!s whether at 
the site of inflammation or systemically (IVIG) are necessary to decipher their 
regulatory efficacy on the immune system. 
The influence of different sialylated IgG subclasses on the development of arthritis 
remains to be investigated.  
 
5.2.3. Mode of Action 
In general, sialylated IgGs might reflect the steady state of a humoral arsenal of 
antibodies. Upon antigen stimulation, production of desialylated antibodies from new 
plasma cells might switch the immune system to an inflammatory state to combat 
pathogens or to trigger autoimmune disease.  21, 23 
There is only little data about the influence of sialylated IgGs on immune cells and 
only one general regulatory cell signalling pathway has been proposed up to now.  22, 
23, 26, 27, 46 SIGN-R1 is a c-lectin receptor on splenic marginal zone macrophages that 
can bind to sialylated IgGs and triggers the upregulation of inhibitory Fc!RIIB on 
effector macrophages. A switch in the balance from activating to increased inhibitory 
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signalling upon IgG binding could mark a possible effector mechanism of IVIG, but 
the human homolog DC-SIGN has a different expression pattern (expressed on 
dentritic cells) and thus results can not be translated from mouse to human.  
In our experiments we could show antiinfllammatory effects of sialylated antigen-
specific IgG1 antibodies in Fc!RIIB-/- mice, strongly suggesting a further interaction 
pathway contributing to the antiinflammatory activity – especially in an antigen-
specific manner. The reduced binding affinity of sialylated IgG1!s to the activating 
Fc!RIII and the blocked Fc!RIV signalling 9, 20 may account for some of the effects but 
would not explain active inhibitory modes of action as we observed complete 
inhibition of the development of severe arthritis compared to the control group even at 
time-points, when increased IgG1 levels from the treatment could not be detected 
any more. This would suggest a long lasting regulatory effect of sialylated IgGs to 
maintain suppressor functions even after natural degradation of the injected 
biologics.  
Interestingly, in healthy and arthritic mice the humoral immune response against 
chicken CII (chCII) and mouse self-CII (mCII) was at comparable levels. Even healthy 
or treated mice hat elevated levels of all Ig isotypes and subclasses. Mice treated 
with sialylated IgG1 had reduced IgG levels at the end of the experiment. These 
findings are consistent with the suggestion that sialylated IgG1 has a regulatory 
function and prolonged inflammatory IgG production is reduced. Investigations on the 
role of Tregs and regulatory macrophages would be of particular interest as well as 
examinations on the regulatory properties of B-cells.  
 
Healthy and sick mice did significantly differ in their humoral immune response at 
IgG2a and IgG2b levels, which have been described to have pathogenic properties in 
autoimmune diseases.  10  
A prognostically relevant observation was that sialylated IgG1 might directly trigger 
IgM production against self-antigen mCII at early time-points (day 12)  – before the 
onset of the disease (around day 20), which later might prevent the mice from severe 
arthritis. This correlates with our findings that mice receiving sialylated anti-CII IgG1 
before disease onset have a better clinical prognosis and that they have increasee 
anti-mCII IgM antibodies.  One possible mechanism of action of sialylated IgG1 could 
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thus be the trigger of “natural” IgM production that prevents mice from developing 
pathological immune responses against self-antigen mCII, because the purpose of 
IgM is non-inflammatory antigen clearance. 47 Sialylated antibodies might have a 
direct influence on B-cells, which upon expression of protecting “natural” IgM could 
have a regulatory role during an immune response.  
 
If certain arthritogenic epitopes on CII account for any effects is unclear. Additionally 
to B-cell epitopes (antibody epitopes) there are T-cell epitopes on CII  29, 43, 48, 49 that 
might be sterically blocked upon binding of anti-CII antibodies.  
CIA arthritis also evokes a T-cell response during the establishment of inflammation 
in the joints. 29, 39, 44 But only little is known about the influence of sialylated antibodies 
on T-cells – especially regulatory T-cells (Tregs) and proinflammatory Th17-cells. 27  
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Figure 21 Supposed mechanisms of action of intravenous immunoglobulin (IVIG) on cellular 
immunity. 23 Besides the many proposed interactions of sialylated IgG!s with different cell 
types of the adaptive and innate immune system depicted in this figure, we suggest novel 
unidentified modes of action of antigen-specific sialylated IgG antibodies, because our results 
have excluded the inhibitory Fc!-receptor IIB as regulatory downstream signal of sialylated 
IgG!s. Up to now there exist several proposed modes of action, but only few publications 
have suggested direct or indirect interactions and regulation mechanisms of sialylated IgG!s 
with B-cells, T-cells, peripheral macrophages and other components of the immune system.  
 
 
5.2.4. Perspectives for Medical Applications 
Up to now approved antigen-specific antibody biologics have been designed to tag 
antigenic structures for depletion. In chronic inflammatory autoimmune diseases 
therapeutic antibodies are used to target proinflammatory cytokines or immune cells. 
Sialylated IgGs now provide a novel tool for actively transferring tolerance to an 
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antigenic structure. Translational medicine research in the field of autoimmune 
diseases will outcome screening methods to individually determine antigenic 
structures in antibody-mediated autoimmune diseases like rheumatoid arthritis. The 
design of antigen-specific sialylated antibodies thereafter can be the base of a 
completely new approach to patient-oriented treatment of multiple autoimmune 
diseases. Individualized medical therapeutics are necessary to target the causes of 
disease.  
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Abbreviations 
 
AA Acrylamide/bisacrylamide 
AgeI Restriction enzyme 
anit-CII-cc Desialylated anti-collagen type II antibody (cell culture produced) 
anti-CII Anti-collagen type II antibody 
anti-CII-sial Sialylated anti-collagen type II antibody (enzymatic. glycosylated) 
Asn Asparagine 
bCII Bovine collagen type II 
BsiWI Restriction enzyme 
C18 Carbohydrate of 18 carbon atoms 
C57BL/6 Black-6 mouse strain 
CDR Complementary determining region 
CFA Complete Freund's adjuvants 
CFU Colony forming unit 
CH1 Heavy chain constant domain 1 
chCII Chicken collagen type II 
CIA Collagen-induced arthritis 
CII Collagen type II 
CL Light chain constant domain 
CMP Cytidine monophosphate 
CO2 Carbon dioxide 
C-region Constant region 
DC-SIGN Dentritic cell specific ICAM-3 grabbin non-integrin related 
ddH2O Destilled deionized water 
DMEM Dulbecco/Vogt modified Eagle's minimal essential medium 
dsDNA Double strand DNA 
ELISA Enzyme-linked immunosorbant assay 
EndoS Endoglycosidase 
Fab Antigen-binding fragmen 
Fc Fragment crystallizable 
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FCS Fetal calf serum 
Fc!RIIB Fc-gamma receptor II B 
G0 Fc-glycan with terminal N-acetylglucosamines 
G1 Fc-glycan with one terminal galactose 
G2 Fc-glycan with two terminal galactoses 
GlcNac N-acetylglucosamine 
H-2
b
 MHC haplotype 
H2SO4 Sulfuric acid 
H37Ra Mycobacterium tuberculosis strain 
HC heavy chin 
hCII Human collagen type II 
HCl Hydrogen chloride 
HCMV Human cytomegalo virus 
HEK293T Human embryonic kidney cells with T-antigen 
HindIII Restriction enzyme 
HRP Horseradish peroxidase 
IFA Incomplete Freund's adjuvants 
Ig Immunoglobulin 
IgG Immunoglobulin G 
IgH Immunoglobulin heavy chain 
IgL Immunoglobulin light chain 
Ig" Immunoglobulin kappa 
IL-1 Interleukin 1 
IL-17 Interleukin 17 
IVIG Intravenous immunoglobulin G 
kDA Kilodalton 
LB Lysogeny broth 
LC light chain 
LPS Lipopolysaccharide 
M Molar = mol/L 
MALDI-TOF Matrix-assisted laser desorption/ionization 
mCII Mouse collagen type II 
MCS Multiple cloning site 
MHC Major histocompatibility complex 
mM Millimolar = mmol/L 
N-linked Chemical bound via nitrogen 
OD Optical density 
PAD Peptidyl arginine deaminase 
PAGE Polyacrylamide gel electrophoresis 
PBS Phosphate buffered saline 
PCR Polymerase chain reaction 
PEI Polyethylenimine 
S1 Fc-glycan with one terminal sialic acid 
SalI Restriction enzyme 
SDS Sodium dodecyl sulfate  
SIGN-R1 Specific ICAM-3 grabbin non-integrin related 1 
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SOC Super optimal broth 
ssDNA Single strand DNA 
St6Gal1 Beta-1,6-sialyltransferase 
TAE Tris acetate EDTA 
TLR2 Toll-like receptor 2 
TMB 3,3',5,5'-Tetramethylbenzidine 
TNF-# Tumor necrosis factor alpha 
U Unit 
UDP Uracile diphosphate 
VDJ Variable-diversity-joining 
VH Variable region of heavy chain 
VJ Variable-joining 
VL Variable region of light chain 
V-region Variable region 
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 Erfahrung im experimentellen Umgang mit Mäusen (z.B. Kollagen-induzierte 
Arthritis) 
 
Stipendien 
Diplomarbeit  Stipendium der Universität Wien für wissenschaftliche Arbeiten im Ausland  
Austauschstudium Erasmus-Stipendium des Österreichischen Austauschdienstes (ÖAD). 
 Studentenaustauschförderung des Landes  
 
 
 
 
 
 
Felix Lorenz              Wien, April 2010 
 
 
 
